UCLA UCLA Previously Published Works

Title

High-Throughput Parallel Sequencing to Measure Fitness of Leptospira interrogans Transposon Insertion Mutants during Acute Infection

Permalink https://escholarship.org/uc/item/33s941jw

Journal PLOS Neglected Tropical Diseases, 10(11)

ISSN 1935-2727

Authors

Lourdault, Kristel Matsunaga, James Haake, David A

Publication Date

2016

DOI

10.1371/journal.pntd.0005117

Peer reviewed

CrossMark

OPEN ACCESS

Citation: Lourdault K, Matsunaga J, Haake DA (2016) High-Throughput Parallel Sequencing to Measure Fitness of *Leptospira interrogans* Transposon Insertion Mutants during Acute Infection. PLoS Negl Trop Dis 10(11): e0005117. doi:10.1371/journal.pntd.0005117

Editor: Nicholas P. Day, Mahidol University, THAILAND

Received: June 14, 2016

Accepted: October 18, 2016

Published: November 8, 2016

Copyright: This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the <u>Creative</u> <u>Commons CC0</u> public domain dedication.

Data Availability Statement: All relevant data are within the paper and its Supporting Information files.

Funding: This work was supported by a Veterans Affairs Merit Award to DAH (http://www.research. va.gov/services/shared_docs/merit_review.cfm) and a National Institutes of Health grant R01 AI 034431 to DAH (https://www.niaid.nih.gov/ research/research-funded-niaid). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. RESEARCH ARTICLE

High-Throughput Parallel Sequencing to Measure Fitness of *Leptospira interrogans* Transposon Insertion Mutants during Acute Infection

Kristel Lourdault^{1,2}*, James Matsunaga^{1,2}, David A. Haake^{1,2,3,4}

 Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California, United States of America, 2 Departments of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, United States of America, 3 Departments of Urology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, United States of America,
 4 Departments of Microbiology, Immunology, and Molecular Genetics, University of California Los Angeles, Los Angeles, California, United States of America

* kristel.lourdault@gmail.com

Abstract

Pathogenic species of Leptospira are the causative agents of leptospirosis, a zoonotic disease that causes mortality and morbidity worldwide. The understanding of the virulence mechanisms of Leptospira spp is still at an early stage due to the limited number of genetic tools available for this microorganism. The development of random transposon mutagenesis in pathogenic strains a decade ago has contributed to the identification of several virulence factors. In this study, we used the transposon sequencing (Tn-Seq) technique, which combines transposon mutagenesis with massive parallel sequencing, to study the *in vivo* fitness of a pool of Leptospira interrogans mutants. We infected hamsters with a pool of 42 mutants (input pool), which included control mutants with insertions in four genes previously analyzed by virulence testing (loa22, ligB, flaA1, and lic20111) and 23 mutants with disrupted signal transduction genes. We quantified the mutants in different tissues (blood, kidney and liver) at 4 days post-challenge by high-throughput sequencing and compared the frequencies of mutants recovered from tissues to their frequencies in the input pool. Control mutants that were less fit in the Tn-Seg experiment were attenuated for virulence when tested separately in the hamster model of lethal leptospirosis. Control mutants with unaltered fitness were as virulent as the wild-type strain. We identified two mutants with the transposon inserted in the same putative adenylate/guanylate cyclase gene (lic12327) that had reduced in vivo fitness in blood, kidney and liver. Both lic12327 mutants were attenuated for virulence when tested individually in hamsters. Growth of the control mutants and *lic12327* mutants in culture medium were similar to that of the wild-type strain. These results demonstrate the feasibility of screening large pools of L. interrogans transposon mutants for those with altered fitness, and potentially attenuated virulence, by transposon sequencing.

Competing Interests: The authors have declared that no competing interests exist.

Author Summary

Leptospirosis is a neglected infectious disease that sickens many humans and animals throughout the world. It is caused by pathogenic *Leptospira spp*. Few leptospiral genes that contribute to the disease have been identified. We generated a library of 800 *L. interrogans* mutants with transposon insertions in different genes. Screening each mutant individually for the ability to cause disease in the hamster model would be laborious and requires thousands of animals. In a pilot experiment, we infected hamsters with a pool of 42 mutants to determine the role of the disrupted genes on fitness of the bacterium during infection. Out of the 12 mutants with diminished fitness in the three tissues, two had transposon insertions in the gene encoding an enzyme that may generate the small signaling molecule cAMP. When tested separately, the two mutants failed to sicken hamsters, indicating that intracellular cAMP signaling within *L. interrogans* could have a role in causing disease. These findings indicate that large pools of transposon insertion mutants can be screened in a limited number of animals to identify leptospiral genes that may be critical for the disease process.

Introduction

Pathogenic *Leptospira spp* are the causative agents of leptospirosis, presumed to be the most widespread zoonotic disease [1]. Leptospirosis has emerged as a major public health burden in urban slums where risk is strongly linked to poverty and rat exposure [2–4]. It is estimated that there are 1.03 million cases and 58,900 deaths each year from leptospirosis [5]. The disease is transmitted to humans and animals through the urine of infected animals such as rats [1, 6]. Bacteria enter the host via skin abrasions or mucous membranes and then disseminate via the bloodstream to target organs including the lungs, liver and kidneys. Infection produces a range of clinical manifestations, from flu-like symptoms to liver dysfunction, bleeding, kidney failure, pulmonary hemorrhage, and occasionally death [6, 7].

The understanding of the virulence mechanisms of *Leptospira spp* is still at an early stage compared to other bacteria due to the limited number of genetic tools available for leptospires. The sequencing of a large number of leptospiral genomes [8] reveals that genes encoding proteins of unknown functions are enriched among pathogen-specific leptospiral genes [9]. Development of random transposon mutagenesis in pathogenic strains a decade ago has contributed to a better understanding of *Leptospira* biology [10] and has enabled identification of several virulence genes, including *loa22*, the first leptospiral virulence gene to be described [11], and *lb139*, a gene encoding a potential signaling protein [12]. Interestingly, attenuation of virulence did not occur following inactivation of *ligB* or other genes whose products have been shown to have virulence attributes *in vitro* [13]. These results suggest a large degree of functional redundancy of virulence-associated gene products [6, 14].

A disadvantage of virulence testing of individual transposon mutants is that this approach requires the use of a large number of animals. Although animal models remain critical for understanding leptospiral pathogenesis and for identifying virulence factors, there is a need for new approaches to reduce the number of animals required for such experiments.

One strategy to minimize the number of animals is to inoculate pools of mutants into each animal. Recently, Marcsisin *et al.* screened pools of defined *L. interrogans* transposon insertion mutants for infectivity in the hamster model of acute infection [15]. 95 mutants were tested in pools of up to 10 mutants. 25 mutants were also tested in pools of 5 mutants in the mouse

carrier model of infection. This study focused on whether mutants could be detected by PCR in cultures obtained from blood and kidney. Mutants with severe infectivity defects were tested individually for lethal virulence in hamsters. Only one mutant that failed to cause mortality was identified, although death was delayed with another four mutants. Because the level of each mutant was not quantified in the tissues, the approach was biased towards identification of highly attenuated mutants [15].

Transposon sequencing (Tn-Seq) has the potential to identify virulence-attenuated mutants with more subtle effects on infectivity. This technique combines transposon mutagenesis with the power of massive parallel sequencing. The basic principle of transposon sequencing methods involves DNA extraction from the pool of mutants, its cleavage by restriction enzyme digestion or sonication and the addition of adaptors for PCR amplification of the transposon ends and flanking regions. The PCR amplicons are analyzed by high throughput sequencing to determine the insertion site of each mutant and their relative abundance [16–18]. Tn-Seq has been used to study *in vivo* fitness of various bacteria such as *Burkholderia pseudomallei* [19], *Streptococcus pneumoniae* [16], *Haemophilus influenza* [20], and *Borrelia burgdorferi* [21, 22] and to identify bottlenecks during mouse infection by *B. burgdorferi* [23]. Tn-Seq has also been used to identify genes contributing to *in vitro* phenotypes, including antibiotic resistance in *Pseudomonas aeruginosa* [22] and carbon utilization in *B. burgdorferi* [21].

In the present study, we examined the potential of Tn-Seq to quantify the fitness of a pool of leptospiral mutants in various tissues during acute infection of the hamster. We screened mutants with transposon insertions in signal transduction genes to determine whether these genes affect the fitness of *L. interrogans*. The virulence of selected mutants with reduced fitness was tested in the hamster model of acute leptospirosis.

Materials and Method

Bacterial strains and growth medium

The pathogen *Leptospira interrogans* serovar Manilae strain L495 was used as the parent strain for generation of a transposon mutant library. The wild type (WT) strain and all mutants (Table 1) derived from it were grown at 30°C in Ellinghausen-McCullough-Johnson-Harris (EMJH) medium [24, 25] and EMJH supplemented with kanamycin (Km, 50 mg/mL), respectively.

Escherichia coli strain β2163 [26] containing the shuttle vector (pCjTKS2) [27], which carries a *Himar1* transposon, was grown at 37°C in Luria broth supplemented with 2,3-diaminopimelic acid (DAP, 0.3 mM), kanamycin (Km, 50 mg/mL) and spectinomycin (Spc, 50 mg/mL).

Creation of a leptospiral mutant library, and identification of insertion sites

An L495 mutant library was generated by random transposon insertion mutagenesis [28]. Briefly, the shuttle vector pCjTKS2, which contains a *Himar1* element with its transposase gene lying outside of the transposon, was introduced into the L495 strain by conjugation with the *E. coli* β 2163 donor strain. After two to three weeks of growth at 30°C on EMJH+Km plates, colonies were inoculated into EMJH+Km liquid medium and grown at 30°C for three to four weeks. Mutants were separately frozen at -80°C in EMJH and 4% glycerol (final concentration) without passaging.

For each mutant, the insertion site of the transposon in the genome was determined by semi-random PCR as previously described by Slamti *et al.* [28]. PCR primer sequences are provided in the Table 2. The insertion sites were identified by comparing the resulting sequence

Table 1. Transposon mutants used in this study.

Non-signaling genes	LIC number	Chr*	Insertion sites**	Name and Description		
lic1019 chi 20283 log2=-control Ornp.4-family logonotein lic10203 chi 22880 sugar epimerase Nucleoside-diphosphate-sugar epimerase lic10203 chi 258961 <i>AgB</i> -control Bacterial immunogiblin lic10180 chi 158918 <i>AgB</i> -control Enddlegeller illament sheath protein lic11274 chi 157491 <i>ApD</i> -ostrol Enddlegeller illament core protein lic1189 chi 2349578 <i>AcA</i> eflut pump AcA-related membrane protein lic11874 chi 3579630 GTPase GTPase GTPase lic12772 chi 3579637 Acf afflux pump Acf afflux pump Acf afflux pump lic12773 chi 3579637 Acf afflux pump Enddlegeller protein hypothetical protein lic1274 chi 3579637 Acf afflux pump Enddlegeller protein hypothetical protein lic1277 chi 3579637 Acf afflux pump Enddlegeller protein hypothetical protein lic1277 chi 3759877<				Non-signaling genes		
lic10202ch/lS2890/sigar opimeraseNucleoside diphosphate-sugar opimeraselic10484ch/lS2890///gB=-controlBactrial immunoglobinlic10178ch/l95581//gA=-controlEndoflagellar filament sheath proteinlic11021ch/l95583//gA//gDLipoprotein releasing system, LoID ATPase componentlic11274ch/l1574919hypothetical proteinLipoprotein releasing system, LoID ATPase componentlic1189ch/l284578//gA2AcA eflux pumpAcA-related membrane proteinlic11277ch/l3379503GTPaseGIutamete S-Inaselic12773ch/l3379503GTPaseGIutamete S-Inaselic13874ch/l975887Acd eflux pumpEllux pump, Acd familylic13874ch/l178873heme oxygenaseHeme oxygenaselic13874ch/l178873heme oxygenaseCMlic13874ch/l178874adenylate/ganylate cyclaseAC/GClic13874ch/l132244adenylate/ganylate cyclaseAC/GClic13875ch/l2810271adenylate/ganylate cyclaseGAF, AC/GClic12886ch/l2810271adenylate/ganylate cyclaseGAF, AC/GClic12896ch/l303366adenylate/ganylate cyclaseGAF, AC/GClic12896ch/l303360adenylate/ganylate cyclaseGAF, AC/GClic12896ch/l303360adenylate/ganylate cyclaseGAF, AC/GClic12896ch/l </th <th>lic10191</th> <th>chrl</th> <th>220833</th> <th>loa22control</th> <th>OmpA-family lipoprotein</th>	lic10191	chrl	220833	loa22control	OmpA-family lipoprotein	
lic1048 cht 52904 <i>lgd</i> control Bacterali munoglobin lic10788 cht 95581 faA1control Endollagellar filament sheath protein lic11081 cht 1336016 <i>M/D</i> Lipoprotein releasing system, Lo/D ATPase component lic11824 cht 1574819 hypothetical protein Typothetical memt accer protein lic11980 cht 2345578 <i>Aal</i> 2 Endollagellar filament core protein lic12772 cht 3379433 GTBase GTPase GTPase lic12773 cht 375687 Acrd efiltux pump Ellux pump, AcrB family lic13074 cht 375687 Acrd efiltux pump Ellux pump, AcrB family lic13074 cht 375687 Acrd efiltux pump Ellux pump, AcrB family lic13074 cht 375687 Acrd efiltux pump Ellux pump, AcrB family lic13074 cht 30718 ademylate/guanylate cyclase AC/GC lic13082 cht 33561 ademylate/guanylate cyclase AC/GC lic122276	lic10203	chrl	232860	sugar epimerase	Nucleoside-diphosphate-sugar epimerase	
inc10788 chrl 95881 Ma AT—control Endofagellar filament sheath protein lic11881 chrl 1336016 lo/D Licoprotein releasing system, LoID ATPase component lic11882 chrl 1228578 #ab2 Endoflagellar filament sheath protein lic11890 chrl 2289578 #ab2 Endoflagellar filament core protein lic11901 chrl 3379630 GTPase GTPase lic11377 chrl 3379630 GTPase GTPase lic13737 chrl 3379630 GTPase GTPase lic13747 chrl 47058887 Acd9 eflux pump Eflux pump, Acd1 family lic2374 chrl 179673 heme oxygenase Heme oxygenase lic10387 chrl 135224 adenylate/guanylate cyclase AC/GC lic10387 chrl 135224 adenylate/guanylate cyclase AC/GC lic10387 chrl 135224 adenylate/guanylate cyclase AC/GC lic12327 chrl 2810027 adenylate/guanylate cyclase	lic10464	chrl	529904	<i>ligB</i> —control	Bacterial immunogloblin	
lici103 drl li38016 loD Licoprotein Licoprotein Licoprotein Component lic11244 chrl 1574819 hypothetical protein hypothetical protein hypothetical protein lic11846 chrl 2849558 AcrA reliated membrane protein lic11940 chrl 3379603 GTPase GtHamate Skinase lic12773 chrl 375603 GTPase GTPase lic13074 chrl 475561 hypothetical protein hypothetical protein lic13074 chrl 375603 GTPase Omains lic10024 chrl 170573 here oxygenase Domains lic10024 chrl 35244 adenylate/guanylate cyclase GA/GC lic12327 chrl 2810027 <	lic10788	chrl	955881	flaA1—control	Endoflagellar filament sheath protein	
line inspace Inspace Inspace line	lic11081	chrl	1336016	IoID	Lipoprotein releasing system, LoID ATPase component	
initial initial initial initial initial initial initial 	lic11274	chrl	1574819	hypothetical protein	hypothetical protein	
lic11940 chrl 2349558 AcrA efflux pump AcrA related membrane protein lic12772 chrl 3379463 proB glutamate kinase Glutamate Kinase lic12773 chrl 3375603 GTPase GTPase lic13074 chrl 3756887 AcrB efflux pump Efflux pump, AcrB family lic13274 chrl 1015561 hypothetical protein hypothetical protein lic21048 chrl 1015561 hypothetical protein hypothetical protein lic10204 chrl 13718 adenylate/guanylate cyclase TMH, AC/GC lic10204 chrl 3018 adenylate/guanylate cyclase AC/GC lic122270 chrl 2810027 adenylate/guanylate cyclase GAF, AC/GC lic123276 chrl 281027 adenylate/guanylate cyclase FeS, AC/GC, Heme peroxidase lic123276 chrl 3035366 adenylate/guanylate cyclase AC/GC lic123276 chrl 3035366 adenylate/guanylate cyclase AC/GC lic13204 chrl 18	lic11889	chrl	2286578	flaB2	Endoflagellar filament core protein	
lic12772 chrl 3379463 proB glutamate kinase Glutamate 5-kinase lic12773 chrl 3379503 GTPase GTPase lic12374 chrl 375853 ACr2 efflux purp Efflux purp, AcrB family lic1214 chrl 4015561 hypothetical protein hypothetical protein lic2014 chrl 4015561 hypothetical protein hypothetical protein lic2014 chrl 137867 adenylate/guanylate cyclase Domains denotytate/guanylate cyclase adenylate/guanylate cyclase AC/GC lic12257 chrl 2810027 adenylate/guanylate cyclase GAF, AC/GC lic12357 chrl 2810271 adenylate/guanylate cyclase GAF, AC/GC lic12505 chrl 303366 adenylate/guanylate cyclase GAF, AC/GC lic12506 chrl 3633040 adenylate/guanylate cyclase AC/GC lic12608 chrl 3633040 adenylate/guanylate cyclase AC/GC lic120182 chrl 1783180 Signal transduction protein HV-GYP lic101301 chrl 783180 Signal transduction protein Cache_1, GGDEF lic11432 chrl 7789905 Sensor histidire kinase and response regulator of	lic11940	chrl	2349558	AcrA efflux pump	AcrA-related membrane protein	
lic12773 chrl 3379503 GTPase GTPase GTPase lic13247 chrl 3756887 AcrB efflux pump Efflux pump. AcrB efflux pump lic13247 chrl 179873 heme oxygenase Heme oxygenase lic102418 chrl 179873 heme oxygenase Domains denylate/guanylate yclasse Domains Omains lic10024 chrl 30718 adenylate/guanylate cyclase 7TMR, AC/GC lic11022 chrl 2810271 adenylate/guanylate cyclase GAF, AC/GC lic123276 chrl 2810271 adenylate/guanylate cyclase GAF, AC/GC lic12326 chrl 3035366 adenylate/guanylate cyclase FAS, AC/GC lic12407 chrl 3232667 adenylate/guanylate cyclase HAMP, AC/GC lic10304 chrl 305306 adenylate/guanylate cyclase AC/GC lic10410 thrd 755900 GGDEF family protein EAL lic10421 chrl 755905 Sensor histidine kinase and	lic12772	chrl	3379463	proB glutamate kinase	Glutamate 5-kinase	
lic13074 chrl 3756887 Acrß efflux pump Efflux pump, Acrß family lic13274 chrl 4015561 hypothetical protein hypothetical protein lic20148 chrl 179873 heme oxygenase Heme oxygenase Adenylate/yumylate cyclases Signal transduction genes Domains Adenylate/yumylate cyclase Adrylate/guanylate cyclase AC/GC lic11095 chrl 30718 adenylate/guanylate cyclase AC/GC lic123272 chrl 2810027 adenylate/guanylate cyclase GAF, AC/GC lic123275 chrl 2810271 adenylate/guanylate cyclase GAF, AC/GC lic12506 chrl 3853040 adenylate/guanylate cyclase GAF, AC/GC lic12670 chrl 3853040 adenylate/guanylate cyclase HAMP, AC/GC lic10138 chrl 184403 HD-GYP hydrolase domain-containing protein HY-GYP lic10138 chrl 184403 HD-GYP hydrolase domain-containing protein HY-GYP lic10138 chrl 184310 Signal transduction protein EaL lic2031 chrl 18403 HD-GYP hydrolase domain-containing protein HY-GYP lic1138 chrl 1759905 Sensor histidine kinase and respon	lic12773	chrl	3379503	GTPase	GTPase	
lici 13274 chrl 4015561 hypothetical protein home oxygenase Herne oxygenase Herne oxygenase Herne oxygenase Signal transduction genes Signal transduction genes Signal transduction genes CAC/GC Herne peroxidase AC/GC Action 3252667 a demylate/guanylate cyclase AC/GC Action 3252667 a demylate/guanylate cyclase AC/GC Digunylate Cyclase AC/GC Digunylate cyclase AC/GC Action 1 3653040 a demylate/guanylate cyclase AC/GC Digunylate cyclase AC/GC Action 1 54304 Ho-GYP hydrolase domain-containing protein HY-GYP Herne Herne Action Action Component complex Action Component complex Action Component response regulator of a two Component response regulator of a two Component response HK Herne Action 177595 Histidine kinase of a two component regonase MEC, PAS, PAS, PAS, PAS, PAS, PAS, PAS, PAS	lic13074	chrl	3756887	AcrB efflux pump	Efflux pump, AcrB family	
lic20148 chrll 179873 heme oxygenase Signal transduction genes Adenylate/guarylate cyclases Intolo24 chrl 30718 adenylate/guarylate cyclase Intolo24 chrl 30718 adenylate/guarylate cyclase Intolo25 chrl 2810027 adenylate/guarylate cyclase Intol2237 chrl 281027 adenylate/guarylate cyclase Intol2300 chrl 305366 adenylate/guarylate cyclase Intol2300 chrl 3853040 adenylate/guarylate cyclase Intol2300 chrl 3853040 adenylate/guarylate cyclase Intol238 chrl 164403 HD-GYP hydrolase domain-containing protein Hy-GYP Intol41 chrl 783180 Signal transduction protein Intol2018 chrl 175905 Genor histidine kinase and response regulator of a two Component complex Intol231 chrl 2450863 Sensor protein of a two component response regulator of a two Component complex Intol22018 chrl 3178505 Histidine kinase and response regulator of a two Component complex Intol2218 chrl 3178505 Histidine kinase of a two component regulator system Intol2218 chrl 3178505 Histidine kinase of a two component regulator system Intol2205 chrl 3178505 Histidine kinase of a two-component regulator system Intol2205 chrl 3178505 Transcriptional regulator, AcrB-family Intol2205 chrl 35862 Transcriptional regulator, AcrB-family Intol2205 chrl 358682 Transcriptional regulator, AcrB-family Intol2205 chrl 2806250 Signal transduction protein Vetor. Intol2204 chrl 2806250 Signal transduction protein Vetor. Intol2204 chrl 2806250 Signal transduction protein Vetor. Intol2204 chrl 2806250 Signal transduction protein With multiple domains PK, AAA_16, GAF, SpolIE Intol2204 chrl 2806250 Signal tr	lic13274	chrl	4015561	hypothetical protein	hypothetical protein	
Signal transduction genes Domains Adenylate/guanylate cyclases 0718 adenylate/guanylate cyclase 7T/MR, AC/GC lic11095 chrl 13552244 adenylate/guanylate cyclase AC/GC lic12327a chrl 2810027 adenylate/guanylate cyclase GAF, AC/GC lic12327b chrl 2810027 adenylate/guanylate cyclase GAF, AC/GC lic12506 chrl 3035366 adenylate/guanylate cyclase GAF, AC/GC lic12507 chrl 3232667 adenylate/guanylate cyclase HAMP, AC/GC lic12670 chrl 3232667 adenylate/guanylate cyclase HAMP, AC/GC lic12670 chrl 3232667 adenylate/guanylate cyclase AC/GC lic120304 chrl 13232667 adenylate/guanylate cyclase AC/GC lic120305 chrl 132306 Signal transduction protein HX-GYP lic10138 chrl 164030 HD-GYP hydrolase domain-containing protein EAL lic10131 chrl 164030 HD-GYP hydrolase domain-containing protein <	lic20148	chrll	179873	heme oxygenase	Heme oxygenase	
Adenylate/guanylate cyclases Domains lici 10024 chrl 30718 adenylate/guanylate cyclase TTMR, AC/GC lici 11095 chrl 1352244 adenylate/guanylate cyclase GAF, AC/GC lici 12327a chrl 2810271 adenylate/guanylate cyclase GAF, AC/GC lici 12327b chrl 2810271 adenylate/guanylate cyclase GAF, AC/GC lici 12506 chrl 3035366 adenylate/guanylate cyclase FeS, AC/GC, Herne peroxidase lici 12507 chrl 3232667 adenylate/guanylate cyclase FAC/GC lici 12506 chrl 3653040 adenylate/guanylate cyclase AC/GC lici 13004 chrl 3653040 adenylate/guanylate cyclase AC/GC lici 1303 chrl 164403 HD-GYP hydrolase domain-containing protein EAL lici 10138 chrl 1759905 Sensor histidine kinase and response regulator of a two component complex PAS, PAS, PAS, PAS, PAS, PAS, PAS, PAS lici 12231 chrl 1759905 Sensor protein of a two component response regulator PAS, PAS, PAS, PAS, PAS, HK			1	Signal transduction genes		
lic10024 chrl 30718 adenylate/guanylate cyclase TTMR, AC/GC lic11095 chrl 1352244 adenylate/guanylate cyclase AC/GC lic12327a chrl 2810027 adenylate/guanylate cyclase GAF, AC/GC lic12327b chrl 28100271 adenylate/guanylate cyclase GAF, AC/GC lic12506 chrl 3035366 adenylate/guanylate cyclase HAMP, AC/GC lic12670 chrl 365304 adenylate/guanylate cyclase HAMP, AC/GC lic13004 chrl 164403 Adenylate/guanylate cyclase AC/GC Diguanylate cyclases MC/GC Adenylate/guanylate cyclase AC/GC Diguanylate cyclases AC/GC Adenylate/guanylate cyclase AC/GC Diguanylate cyclase AC/GC Adenylate/guanylate cyclase AC/GC Diguanylate cyclase Adenylate/guanylate cycl	Adenylate/	guanyla	te cyclases		Domains	
lic11095 chrl 1352244 adenylate/guanylate cyclase AC/GC lic12327a chrl 2810027 adenylate/guanylate cyclase GAF, AC/GC lic12327b chrl 2810271 adenylate/guanylate cyclase GAF, AC/GC lic1237b chrl 3035366 adenylate/guanylate cyclase FeS, AC/GC, Heme peroxidase lic12670 chrl 3232667 adenylate/guanylate cyclase HAMP, AC/GC lic13004 chrl 3653040 adenylate/guanylate cyclase AC/GC lic13004 chrl 3653040 adenylate/guanylate cyclase AC/GC lic13004 chrl 164403 Bignal transduction protein HY-GYP lic1041 chrl 164403 Signal transduction protein EAL lic21282 chrl 175905 Sensor histidine kinase and response regulator of a two PAS, PAS, HK, REC lic12031 chrl 2450863 Sensor protein of a two component response regulator PAS, PAS, PAS, PAS, HK lic1227a chrl 275805 Histidine kinase of a two-component regulator system REC,	lic10024	chrl	30718	adenylate/guanylate cyclase	7TMR, AC/GC	
lic12327a chrl 2810027 adenylate/guanylate cyclase GAF, AC/GC lic12327b chrl 2810271 adenylate/guanylate cyclase GAF, AC/GC lic12506 chrl 3035366 adenylate/guanylate cyclase FeS, AC/GC, Heme peroxidase lic12670 chrl 305366 adenylate/guanylate cyclase HAMP, AC/GC lic13004 chrl 3653040 adenylate/guanylate cyclase AC/GC Diguanylate cyclase AC/GC Diguanylate cyclase AC/GC Diguanylate cyclase chrl 164403 HD-GYP hydrolase domain-containing protein HY-GYP lic10138 chrl 164403 HD-GYP hydrolase domain-containing protein EAL lic20182 chrll 1783180 Signal transduction protein EAL lic20182 chrll 1759905 Sensor histidine kinase and response regulator of a two PAS, PAS, HK, REC lic12031 chrl 1759905 Sensor histidine kinase of a two-component regulator system REC, PAS, HK lic12627a chrl 3177595 Histidine kinase of a two-component regulator system REC, PAS, HK lic12627b chrl	lic11095	chrl	1352244	adenylate/guanylate cyclase	AC/GC	
lic12327b chrl 2810271 adenylate/guanylate cyclase GAF, AC/GC lic12506 chrl 3035366 adenylate/guanylate cyclase FeS, AC/GC, Heme peroxidase lic12670 chrl 3222667 adenylate/guanylate cyclase HAMP, AC/GC lic13004 chrl 3232567 adenylate/guanylate cyclase AC/GC Diguanylate cyclase=/phosphotiesterases AC/GC lic10138 chrl 164403 HD-GYP hydrolase domain-containing protein HY-GYP lic10148 chrl 783180 Signal transduction protein EAL lic20122 chrl 783180 Signal transduction protein Cache_1, GGDEF Histidine kinase Infile 20752 GGDEF family protein Cache_1, GGDEF lic11432 chrl 1759905 Sensor histidine kinase and response regulator of a two component complex PAS, PAS, PAS, PAS, PAS, PAS, HK lic12218 chrl 2450863 Sensor protein of a two component regulator system REC, PAS, HK lic12627b chrl 3177595 Histidine kinase of a two-component regulator system REC, PAS, HK lic12627b chrl 374434 <td>lic12327a</td> <td>chrl</td> <td>2810027</td> <td>adenylate/guanylate cyclase</td> <td>GAF, AC/GC</td>	lic12327a	chrl	2810027	adenylate/guanylate cyclase	GAF, AC/GC	
lic12506 chrl 3035366 adenylate/guanylate cyclase FeS, AC/GC, Heme peroxidase lic12670 chrl 3232667 adenylate/guanylate cyclase HAMP, AC/GC lic13004 chrl 3653040 adenylate/guanylate cyclase AC/GC Diguanylate cyclases/phosibesterases lic10138 chrl 164403 HD-GYP hydrolase domain-containing protein HY-GYP lic10641 chrl 783180 Signal transduction protein EAL lic20182 chrll 230752 GGDEF family protein Cache_1, GGDEF Histline kinase lic11432 chrl 175905 Sensor histidine kinase and response regulator of a two component complex lic12031 chrl 2450863 Sensor protein of a two component response regulator PAS, PAS, PAS, PAS, PAS, HK lic12627a chrl 3177595 Histidine kinase of a two component response HK lic12627a chrl 3177595 Histidine kinase of a two-component regulator system Transcriptional regulator lic12627a chrl 3178505 Histidine kinase of a two-component regulator system REC, PAS, HK Transcriptional regulator lic12627a chrl 376434 Transcriptional regulator, AcrR-family HTH (TetR family) Alternative of actor lic12522 chrl 3030630 Sigma 54 modulation protein / S30EA ribosomal protein 054 modulation protein lic12324 chrl 268650 RNA polymerase sigma subunit lic12502 chrl 3030630 Sigma 54 modulation protein / S30EA ribosomal protein Phosphatase lic12324 chrl 2806718 Signal transduction protein with multiple domains PK, AAA_16, GAF, SpolIE lic12324 chrl 2806718 Signal transduction protein with multiple domains PK, AAA_16, GAF, SpolIE lic12324 chrl 2806718 Signal transduction protein with multiple domains PK, AAA_16, GAF, SpolIE lic12324 chrl 2806718 Signal transduction protein with multiple domains PK, AAA_16, GAF, SpolIE lic12324 chrl 132731 Regulator of sigma subunit—control HAMP, SpolIE	lic12327b	chrl	2810271	adenylate/guanylate cyclase	GAF, AC/GC	
iic12670 chrl 3232667 adenylate/guanylate cyclase HAMP, AC/GC iic13004 chrl 3653040 adenylate/guanylate cyclase AC/GC Diguanylate cyclasess/bhosphodiesterases iic10138 chrl 164403 HD-GYP hydrolase domain-containing protein HY-GYP iic10641 chrl 783180 Signal transduction protein iic20182 chrl 1230752 GGDEF family protein Cache_1, GGDEF Histidine kinase iic10133 chrl 1759905 Sensor histidine kinase and response regulator of a two component complex iic12218 chrl 1759905 Sensor histidine kinase and response regulator of a two component complex iic12218 chrl 2676839 Sensor histidine kinase of a two component response HK iic12627a chrl 3177595 Histidine kinase of a two-component response HK iic12627b chrl 3177595 Histidine kinase of a two-component regulator system REC, PAS, HK iic12627b chrl 3177595 Histidine kinase of a two-component regulator system REC, PAS, HK iic12627b chrl 317595 Histidine kinase of a two-component regulator system REC, PAS, HK iic12627b chrl 317595 Histidine kinase of a two-component regulator system REC, PAS, HK iic12627b chrl 317695 Histidine kinase of a two-component regulator system REC, PAS, HK iic12627b chrl 317695 Histidine kinase of a two-component regulator system REC, PAS, HK Transcriptional regulator iic13073 chrl 25850 R1NA polymerase sigma subunit ECF-type of factor iic12502 chrl 3030630 Sigma 54 modulation protein / S30EA ribosomal protein d54 modulation protein Phosphatase iic12324 chrl 2806250 Signal transduction protein with multiple domains PK, AAA_16, GAF, SpolIE iic12324 chrl 2806718 Signal transduction protein with multiple domains PK, AAA_16, GAF, SpolIE iic12324 chrl 132731 Regulator of sigma subunit—control HAMP, SpoIIE Other T	lic12506	chrl	3035366	adenvlate/guanvlate cvclase	FeS. AC/GC. Heme peroxidase	
ici 13004 chrl 3653040 adenylate/guanylate cyclase AC/GC Diguanylate cyclases/phosphodiesterases ici 1641 chrl 164403 HD-GYP hydrolase domain-containing protein HY-GYP lic10641 chrl 783180 Signal transduction protein EAL lic20182 chrll 1230752 GGDEF family protein Cache_1, GGDEF Histidine kinase ici 1759905 Sensor histidine kinase and response regulator of a two component complex PAS, PAS, PAS, PAS, PAS, PAS, PAS, PAS,	lic12670	chrl	3232667	adenvlate/guanvlate cvclase	HAMP. AC/GC	
Diguanylate cyclases/phosphodiesterases Diguanylate cyclases/phosphodiesterases Note that the experimental term of the experiment of the experimente term of the experimental term of the experi	lic13004	chrl	3653040	adenvlate/guanvlate cvclase	AC/GC	
Ici10138 chrl 164403 HD-GYP hydrolase domain-containing protein HY-GYP Iic10641 chrl 783180 Signal transduction protein EAL Iic20182 chrll 230752 GGDEF family protein Cache_1, GGDEF Histidine kinase Iic20182 chrll 1759905 Sensor histidine kinase and response regulator of a two component complex PAS, PAS, PAS, PAS, PAS, PAS, PAS, PAS,	Diquanvlat	e cvclas	es/phosphodies	sterases		
lic10641 chrl 783180 Signal transduction protein EAL lic20182 chrll 230752 GGDEF family protein Cache_1, GGDEF Histidine kinase Intervention Cache_1, GGDEF Cache_1, GGDEF Histidine kinase Intervention Cache_1, GGDEF Cache_1, GGDEF Iic1031 chrl 1759905 Sensor histidine kinase and response regulator of a two component complex PAS, PAS, PAS, PAS, PAS, PAS, PAS, PAS,	lic10138	chrl	164403	HD-GYP hydrolase domain-containing protein	HY-GYP	
lic20182 chrll 230752 GGDEF family protein Cache_1, GGDEF Histidine kinase I 1759905 Sensor histidine kinase and response regulator of a two component complex PAS, PAS, PAS, PAS, PAS, HK, REC lic12031 chrl 2450863 Sensor protein of a two component response regulator PAS, PAS, PAS, PAS, PAS, HK lic12018 chrl 2676839 Sensor histidine kinase of a two component response regulator PAS, PAS, PAS, PAS, HK lic12627a chrl 3177595 Histidine kinase of a two-component regulator system REC, PAS, HK lic12627b chrl 3177595 Histidine kinase of a two-component regulator system REC, PAS, HK lic12627b chrl 3178505 Histidine kinase of a two-component regulator system REC, PAS, HK lic12627b chrl 3178505 Histidine kinase of a two-component regulator system REC, PAS, HK lic12627b chrl 3754434 Transcriptional regulator, AcrR-family HTH (TetR family) Alternative of factor	lic10641	chrl	783180	Signal transduction protein	EAL	
Histidine kinase Intervention Participation Participation lic11432 chrl 1759905 Sensor histidine kinase and response regulator of a two component complex PAS, PAS, PAS, PAS, PAS, PAS, PAS, PAS,	lic20182	chrll	230752	GGDEF family protein	Cache 1. GGDEF	
lic11432 chrl 1759905 Sensor histidine kinase and response regulator of a two component complex PAS, PAS, HK, REC lic12031 chrl 2450863 Sensor protein of a two component response regulator PAS, PAS, PAS, PAS, PAS, HK lic12218 chrl 2676839 Sensor protein of a two component response HK lic12627a chrl 3177595 Histidine kinase of a two-component regulator system REC, PAS, HK lic12627b chrl 3178505 Histidine kinase of a two-component regulator system REC, PAS, HK lic12627b chrl 3178505 Histidine kinase of a two-component regulator system REC, PAS, HK lic12627b chrl 3178505 Histidine kinase of a two-component regulator system REC, PAS, HK lic12627b chrl 3178505 Histidine kinase of a two-component regulator system REC, PAS, HK lic12627b chrl 3754434 Transcriptional regulator, AcrR-family HTH (TetR family) Alternative o factor lic1032 chrl 158862 Transcriptional regulator GAF, o54 activator, HTH_8 lic10225 chrl 258550 RNA polymerase sigma subunit ECF-type o factor d54 modulation	Histidine ki	nase				
lic12031 chrl 2450863 Sensor protein of a two component response regulator PAS, PAS, PAS, PAS, HK lic12218 chrl 2676839 Sensor histidine kinase of a two component response HK lic12627a chrl 3177595 Histidine kinase of a two-component regulator system REC, PAS, HK lic12627b chrl 3178505 Histidine kinase of a two-component regulator system REC, PAS, HK lic12627b chrl 3178505 Histidine kinase of a two-component regulator system REC, PAS, HK lic12627b chrl 3178505 Histidine kinase of a two-component regulator system REC, PAS, HK lic12627b chrl 3178505 Histidine kinase of a two-component regulator system REC, PAS, HK lic12627b chrl 3764434 Transcriptional regulator, AcrR-family HTH (TetR family) Alternative or factor Ic1032 chrl 158862 Transcriptional regulator GAF, o54 activator, HTH_8 lic10225 chrl 258550 RNA polymerase sigma subunit ECF-type o factor o54 modulation protein lic12324a chrl 2806500 Signal transduction protein with multiple domains PK, AAA_16, GAF, SpolIE	lic11432	chrl	1759905	Sensor histidine kinase and response regulator of a two component complex	PAS, PAS, HK, REC	
lic12218 chrl 2676839 Sensor histidine kinase of a two component response HK lic12627a chrl 3177595 Histidine kinase of a two-component regulator system REC, PAS, HK lic12627b chrl 3178505 Histidine kinase of a two-component regulator system REC, PAS, HK Transcriptional regulator Italian e kinase of a two-component regulator system REC, PAS, HK Transcriptional regulator Italian e kinase of a two-component regulator system REC, PAS, HK lic13073 chrl 3754434 Transcriptional regulator, AcrR-family HTH (TetR family) Alternative σ factor Italian e kinase sigma subunit ECF-type of factor Italian e component regulator lic10225 chrl 158862 Transcriptional regulator GAF, σ54 activator, HTH_8 lic12022 chrl 3030630 Sigma 54 modulation protein / S30EA ribosomal protein σ54 modulation protein Phosphatase Italian e component regulator of sigma subunit ECF-type of factor Italian e component regulator lic12324a chrl 2806250 Signal transduction protein with multiple domains PK, AAA_16, GAF, SpollE lic20111 chrl 132731 Regulato	lic12031	chrl	2450863	Sensor protein of a two component response regulator	PAS, PAS, PAS, PAS, HK	
lic12627a chrl 3177595 Histidine kinase of a two-component regulator system REC, PAS, HK lic12627b chrl 3178505 Histidine kinase of a two-component regulator system REC, PAS, HK Transcriptional regulator ic13073 chrl 3754434 Transcriptional regulator, AcrR-family HTH (TetR family) Alternative σ factor ic10132 chrl 158862 Transcriptional regulator GAF, σ54 activator, HTH_8 lic12252 chrl 258550 RNA polymerase sigma subunit ECF-type σ factor lic12502 chrl 3030630 Sigma 54 modulation protein / S30EA ribosomal protein σ54 modulation protein Phosphatase ic12324a chrl 2806250 Signal transduction protein with multiple domains PK, AAA_16, GAF, SpoIIE lic20111 chrl 132731 Regulator of sigma subunit—control HAMP, SpoIIE Other virtual domains PK, AAA_16, GAF, SpoIIE Virtual domains Virtual domains	lic12218	chrl	2676839	Sensor histidine kinase of a two component response	НК	
lic12627b chrl 3178505 Histidine kinase of a two-component regulator system REC, PAS, HK Transcriptional regulator ic13073 chrl 3754434 Transcriptional regulator, AcrR-family HTH (TetR family) Alternative σ factor ic10132 chrl 158862 Transcriptional regulator GAF, σ54 activator, HTH_8 lic10225 chrl 158862 Transcriptional regulator GAF, σ54 activator, HTH_8 lic12202 chrl 3030630 Sigma 54 modulation protein / S30EA ribosomal protein σ54 modulation protein Phosphatase ic12324a chrl 2806250 Signal transduction protein with multiple domains PK, AAA_16, GAF, SpolIE lic20111 chrl 132731 Regulator of sigma subunit—control HAMP, SpolIE Other	lic12627a	chrl	3177595	Histidine kinase of a two-component regulator system	REC, PAS, HK	
Transcriptional regulator Transcriptional regulator lic13073 chrl 3754434 Transcriptional regulator, AcrR-family HTH (TetR family) Alternative σ factor Internative σ factor Internative σ factor Internative σ factor lic10132 chrl 158862 Transcriptional regulator GAF, σ54 activator, HTH_8 lic10225 chrl 258550 RNA polymerase sigma subunit ECF-type σ factor lic12502 chrl 3030630 Sigma 54 modulation protein / S30EA ribosomal protein σ54 modulation protein Phosphatase Internative σ factor Internative σ factor Internative σ factor lic12324a chrl 2806250 Signal transduction protein with multiple domains PK, AAA_16, GAF, SpoIIE lic20111 chrl 2806718 Signal transduction protein with multiple domains PK, AAA_16, GAF, SpoIIE lic20111 chrll 132731 Regulator of sigma subunit—control HAMP, SpoIIE Other Internative of sigma subunit—control Different in the hold of the option of the hold o	lic12627b	chrl	3178505	Histidine kinase of a two-component regulator system	REC, PAS, HK	
lic13073 chrl 3754434 Transcriptional regulator, AcrR-family HTH (TetR family) Alternative σ factor ic10132 chrl 158862 Transcriptional regulator GAF, σ54 activator, HTH_8 lic10132 chrl 258550 RNA polymerase sigma subunit ECF-type σ factor lic12502 chrl 3030630 Sigma 54 modulation protein / S30EA ribosomal protein σ54 modulation protein Phosphatase ic12324a chrl 2806250 Signal transduction protein with multiple domains PK, AAA_16, GAF, SpolIE lic20111 chrl 2806718 Signal transduction protein with multiple domains PK, AAA_16, GAF, SpolIE lic20111 chrl 132731 Regulator of sigma subunit—control HAMP, SpolIE Other	Transcripti	onal reg	gulator			
Alternative o factor GAF, o54 activator, HTH_8 lic10132 chrl 158862 Transcriptional regulator GAF, o54 activator, HTH_8 lic10225 chrl 258550 RNA polymerase sigma subunit ECF-type o factor lic12502 chrl 3030630 Sigma 54 modulation protein / S30EA ribosomal protein o54 modulation protein Phosphatase I I 2806250 Signal transduction protein with multiple domains PK, AAA_16, GAF, SpolIE lic12324b chrl 2806718 Signal transduction protein with multiple domains PK, AAA_16, GAF, SpolIE lic20111 chrll 132731 Regulator of sigma subunit—control HAMP, SpolIE Other	lic13073	chrl	3754434	Transcriptional regulator, AcrR-family	HTH (TetR family)	
lic10132 chrl 158862 Transcriptional regulator GAF, σ54 activator, HTH_8 lic10225 chrl 258550 RNA polymerase sigma subunit ECF-type σ factor lic12502 chrl 3030630 Sigma 54 modulation protein / S30EA ribosomal protein σ54 modulation protein Phosphatase	Alternative	σ facto	r			
lic10225 chrl 258550 RNA polymerase sigma subunit ECF-type σ factor lic12502 chrl 3030630 Sigma 54 modulation protein / S30EA ribosomal protein σ54 modulation protein Phosphatase lic12324a chrl 2806250 Signal transduction protein with multiple domains PK, AAA_16, GAF, SpolIE lic12324b chrl 2806718 Signal transduction protein with multiple domains PK, AAA_16, GAF, SpolIE lic20111 chrll 132731 Regulator of sigma subunit—control HAMP, SpolIE Other	lic10132	chrl	158862	Transcriptional regulator	GAF, σ54 activator, HTH_8	
lic12502 chrl 3030630 Sigma 54 modulation protein / S30EA ribosomal protein σ54 modulation protein Phosphatase lic12324a chrl 2806250 Signal transduction protein with multiple domains PK, AAA_16, GAF, SpolIE lic12324b chrl 2806718 Signal transduction protein with multiple domains PK, AAA_16, GAF, SpolIE lic20111 chrll 132731 Regulator of sigma subunit—control HAMP, SpolIE Other	lic10225	chrl	258550	RNA polymerase sigma subunit	ECF-type σ factor	
Phosphatase Phosphatase lic12324a chrl 2806250 Signal transduction protein with multiple domains PK, AAA_16, GAF, SpolIE lic12324b chrl 2806718 Signal transduction protein with multiple domains PK, AAA_16, GAF, SpolIE lic20111 chrl 132731 Regulator of sigma subunit—control HAMP, SpolIE Other Intersection of the section of the sect	lic12502	chrl	3030630	Sigma 54 modulation protein / S30EA ribosomal protein	σ54 modulation protein	
lic12324a chrl 2806250 Signal transduction protein with multiple domains PK, AAA_16, GAF, SpollE lic12324b chrl 2806718 Signal transduction protein with multiple domains PK, AAA_16, GAF, SpollE lic20111 chrl 132731 Regulator of sigma subunit—control HAMP, SpollE Other	Phosphata	se			p a series p a series a serie	
lic12324b chrl 2806718 Signal transduction protein with multiple domains PK, AAA_16, GAF, SpollE lic20111 chrll 132731 Regulator of sigma subunit—control HAMP, SpollE Other	lic12324a	chrl	2806250	Signal transduction protein with multiple domains	PK. AAA 16. GAF. SpollE	
lic20111 chrll 132731 Regulator of sigma subunit—control HAMP, SpollE Other Interview Interview Interview	lic12324b	chrl	2806718	Signal transduction protein with multiple domains	PK. AAA 16. GAF. SpollE	
Other Descence regulate with UD_OVD descent DUIS2004_UD (shared bit)	lic20111	chrll	132731	Regulator of sigma subunit—control	HAMP. SpollE	
	Other				,	
IICT 1903 CONTENT 1923334 Response regulator with HD-GYP gomain DUF3391. HD (phosphohydrolase)	lic11563	chrl	1923334	Response regulator with HD-GYP domain	DUF3391, HD (phosphohydrolase)	

(Continued)

Table 1. (Continued)

Chr*	Insertion sites**	Name and Description			
Intergenic regions					
chrl	953546	Intergenic-between lepic0802/lic10786 genes			
chrl	1175475	Intergenic-between lic10973/lic10974 genes			
chrl	3104330	Intergenic-between lic12561/lepic2609 genes			
chrl	4004549	Intergenic-between lic13264/lepi3326 genes			
chrl	4230621	Intergenic-between lic13452/lic13453 genes			
chrll	159644	Intergenic-between lepic0137/lic20136 genes			
	Chr* ChrI ChrI ChrI ChrI ChrI ChrI ChrI ChrI	Chr* Insertion sites** chrl 953546 chrl 1175475 chrl 3104330 chrl 4004549 chrl 4230621 chrll 159644	Chr*Insertion sites**Name and DescriptionName and Descriptionchrl953546Intergenic regionschrl953546Intergenic—between lepic0802/lic10786 geneschrl1175475Intergenic—between lic10973/lic10974 geneschrl3104330Intergenic—between lic12561/lepic2609 geneschrl4004549Intergenic—between lic13264/lepi3326 geneschrl4230621Intergenic—between lic13452/lic13453 geneschrll159644Intergenic—between lepic0137/lic20136 genes		

*chr: chromosome (I or II)

** nucleotide of the insertion site in the Fiocruz L1-130 genome.

doi:10.1371/journal.pntd.0005117.t001

with the *L. interrogans* serovar Copenhageni Fiocruz L1-130 genome using the SpiroScope database (http://www.genoscope.cns.fr/agc/mage) [29].

Ethics statement and endpoint criteria

All animals were routinely cared for according to the guidelines provided in the National Institutes of Health Guide to Laboratory Animal Care. Procedures involving hamsters were approved by the Veterans Affairs Greater Los Angeles Healthcare System Institutional Animal Care and Use Committee (protocol #09018–14). Hamsters were weighed daily and observed for endpoint criteria, including loss of appetite, gait or breathing difficulty, prostration, ruffled fur, or weight loss of >10% of maximum weight. Animals that met any of the endpoint criteria were euthanized by isoflurane inhalation followed by thoracotomy.

Animal experiments

Tn-Seq. For this experiment, 42 L495 mutants with *Himar1* insertions in 33 ORFs and 6 intergenic regions were selected (Table 1) and recovered from storage at -80°C by growing them individually in EMJH+Km at 30°C. On the challenge day, leptospires were counted by dark-field microscopy as described by Miller [33]. Briefly 10 μ l of each culture was diluted into 490 μ l PBS. 10 μ l of the suspension was placed on a slide and covered with a coverslip, and the bacterial cells counted with the 40x objective under an Axio Lab A1 microscope with a dark-field condenser (Zeiss). Bacterial counts from five fields were averaged, and the culture density was calculated based on the diameter of the field of view and the volume of suspension under the coverslip. Cultures were then diluted in EMJH to a concentration of 10⁶/mL and pooled together in equal amounts.

Eight four-week-old female Golden Syrian hamsters (Envigo RMS) were challenged intraperitoneally with 1 mL of the pool of mutants, i.e 10^6 leptospires total. Hamsters were monitored daily until day 4 when they were terminated. At the time of sacrifice, kidney and liver were collected into cryotubes and stored at -80°C until use. Blood was collected in EDTA (BD vacutainer Plus Plastic K₂ EDTA tubes), and DNA was immediately extracted (see below). A fraction of the blood was collected in dry tubes and the serum was obtained by centrifugation at 21,130 x g for 15 min and stored at -80°C until use.

On the challenge day, 10 mL of the input pool was spun down for 20 min at 3,220 x g, and the pellet was stored at -80°C until use.

Survival experiment. Hamsters in groups of six were challenged intraperitoneally with 10⁶ leptospires: *loa22*::Tn, *ligB*::Tn, *flaA1*::Tn, *lic20111*::Tn, *lic12327a*::Tn, *lic12327b*::Tn or the

Table 2. Primers used in this study.

Name	Sequence (5'-3')	Reference				
Primers used for semi-random PCR						
TnK1	CTTGTCATCGTCATCCTTG	[28]				
Tnk2	GTGGCTTTATTGATCTTGGG					
Deg1	GGCCACGCGTCGACTAGTACNNNNNNNNNGATAT					
Deg2	GGCCACGCGTCGACTAGTACNNNNNNNNNTCTT					
TnkN1	CGTCATGGTCTTTGTAGTCTATGG					
TnKN2	TGGGGATCAAGCCTGATTGGG					
Тад	GGCCACGCGTCGACTAGTAC					
Primers used	for Illumina sequencing					
TnkN3	CGGGGAAGAACAGTATGTCGAGCTATTTTTTGACTTACTGGGGATCAAGCCTGATTGGG	This study				
olj376	GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTGGGGGGGG	[23]				
pMargent2	AATGATACGGCGACCACCGAGATCTACACTCTTTCCGGGGACTTATCAGCCAACCTGTTA					
IP 1	CAAGCAGAAGACGGCATACGAGATCGGGAGTGGACTGGAGTTCAGACGTGTGCTCTTCCGATCT	Illumina sequencing (barcodes				
IP 2	CAAGCAGAAGACGGCATACGAGAT ACATCG GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT	in bold)				
IP 3	CAAGCAGAAGACGGCATACGAGAT GCCTAA GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT					
IP 4	CAAGCAGAAGACGGCATACGAGAT TGGTCA GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT					
IP 5	CAAGCAGAAGACGGCATACGAGAT CACTGT GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT					
IP 6	CAAGCAGAAGACGGCATACGAGATATTGGCGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT					
IP 7	CAAGCAGAAGACGGCATACGAGAT GATCTG GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT					
IP 8	CAAGCAGAAGACGGCATACGAGAT TCAAGT GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT					
IP 9	CAAGCAGAAGACGGCATACGAGAT CTGATC GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT					
IP 10	CAAGCAGAAGACGGCATACGAGATAAGCTAGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT					
IP 11	CAAGCAGAAGACGGCATACGAGAT GTAGCC GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT					
IP 12	CAAGCAGAAGACGGCATACGAGAT TACAAG GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT					
IP 13	CAAGCAGAAGACGGCATACGAGAT TTGACT GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT					
IP 14	CAAGCAGAAGACGGCATACGAGAT GGAACT GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT					
IP 15	CAAGCAGAAGACGGCATACGAGAT TGACAT GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT					
IP 16	CAAGCAGAAGACGGCATACGAGAT GGACGG GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT					
IP 17	CAAGCAGAAGACGGCATACGAGATCTCTACGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT					
IP 18	CAAGCAGAAGACGGCATACGAGAT GCGGAC GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT					
IP 19	CAAGCAGAAGACGGCATACGAGAT TTTCAC GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT					
IP 20	CAAGCAGAAGACGGCATACGAGAT GGCCAC GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT					
IP 21	CAAGCAGAAGACGGCATACGAGAT CGAAAC GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT					
IP 22	CAAGCAGAAGACGGCATACGAGAT CGTACG GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT					
IP 23	CAAGCAGAAGACGGCATACGAGAT CCACTC GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT					
IP 24	CAAGCAGAAGACGGCATACGAGAT GCTACC GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT					
IP 25	CAAGCAGAAGACGGCATACGAGATATCAGTGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT					
IP 26	CAAGCAGAAGACGGCATACGAGATGCTCATGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT					
IP 27	CAAGCAGAAGACGGCATACGAGATAGGAATGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT					
IP 28	CAAGCAGAAGACGGCATACGAGAT CTTTTG GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT					
IP 29	CAAGCAGAAGACGGCATACGAGAT TAGTTG GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT					
IP seq	GATCGGAAGAGCACACGTCTGAACTCCAGTCAC					
pMargent3	ACACTCTTTCCGGGGACTTATCAGCCAACCTGTTA	[23]				
Primers used	for quantitative PCR					
LipL32-45F	AAGCATTACCGCTTGTGGTG	[30]				
LipL32-286R	GAACTCCCATTTCAGCGATT					
LipL32-189P	[6-FAM]AAAGCCAGGACAAGCGCCG[BHQ1a-Q]					

(Continued)

Table 2. (Continued)

Name	Sequence (5'-3')	Reference					
Primers used for quantitative Real time PCR							
RTIic20110-F	ATCCGCCTTTTAGAACACGC	This study					
RTIic20110-R	TTTGCAAATACGGTTCCGGG						
RTIic20109-F	AACCGGTATCTCAGAGCCTC						
RTIic20109-R	GAACCGAAATGCCACCTTCA						
RTIic20108-F	ATTGATGAAGGGGCGAGAGT						
RTIic20108-R	AATCGGGCTAGGAATTGCGT						
RTrpoB-F	ATGGAGCGGAACGTGTAGTC	[31]					
RTrpoB-R	CTTCGTTCGTTCCATGTCCT						
RTflaB-F	GAGAGAAACACCGAAGACGG	[32]					
RTflaB-R	TGAATAGCAAGAACCCGGAT						

doi:10.1371/journal.pntd.0005117.t002

WT strain. The animals were monitored daily until endpoint criteria were met or for 28 days, at which time they were euthanized. At the time of sacrifice, one kidney was collected and cultured in semisolid Probumin Vaccine-grade Solution (Millipore) containing 100 μ g/mL of 5-fluorouracil and 0.2% Bacto-Agar at 30°C. Cultures were checked weekly for a month for leptospiral growth.

Construction of genomic library for sequencing

Genomic libraries for sequencing were constructed as described by Troy *et al.* [23]. Genomic DNA was extracted from 100 μ l of blood, 25 mg of tissue or frozen pellet from input pool with the DNeasy blood and tissue kit (Qiagen, Valencia, CA) following the manufacturer's instructions except that an elution volume of only 100 μ l was used. Extracted DNA was stored at -80°C until use.

 $50 \ \mu$ l of extracted DNA was sheared by sonication with a Fisher Scientific Model 505 Sonic Dismembrator for 3 min (10 s on and 5 s off; intensity, 80%) in a high-intensity cup horn that was cooled at 4°C. Cytosine tails (C-tails) were added to 500 ng of sheared DNA using terminal deoxynucleotidyl transferase (TdT) (Promega, Madison, WI). The TdT reaction mixture containing 475 μ M dCTP and 25 μ M ddCTP (Affymetrix/USB Products, Santa Clara, CA) was incubated for 1 h at 37°C followed by 20 min at 75°C. The DNA was then purified using the Qiagen MinElute PCR Purification kit (Qiagen, Valencia, CA) following the manufacturer's instructions.

The insertion site of the transposon was amplified by nested PCR. The first PCR was performed with 3 μ l of the C-tailed DNA as template using olj376 and TnKN3 primers (Table 2) specific for the C-tail and the *Himar1* transposon, respectively, in a final volume of 25 μ l. Primer olj376, at the concentration of 1.8 μ M, was added at three times in excess of TnKN3 (600 nM). Reactions were performed using DreamTaq Master Mix (Thermo Scientific) with an initial incubation of 2 min at 95°C followed by 24 cycles of 30 s at 95°C, 30 s at 60°C, and 2 min at 72°C followed by a 2-min extension at 72°C. The second PCR was performed with 2 μ l from the previous PCR step with pMArgent2 primer (600 nM) specific for the end of the transposon and an indexing primer (600 nM) containing the specific sequences required for sequencing on an Illumina platform and a six-base-pair barcode sequence allowing all 37 samples to be multiplexed in a single sequencing lane (Table 2). PCR reactions were performed using DreamTaq Master Mix (Thermo Scientific) with an initial incubation of 2 min at 95°C followed by 18 cycles of 30 s at 95°C, 30 s at 60°C, and 2 min at 72°C followed by a 2-min extension at 72°C. PCR products were purified using a QIAquick PCR purification kit (Qiagen, Valencia, CA) following the manufacturer's instructions except that an elution volume of only 30 µl was used. The majority of PCR products were between 200 bp and 600 bp in size. The DNA concentration of each culture and tissue library was measured with the Qubit 2.0 fluorometer (Thermo Fisher). Equal amounts of DNA from each library were then pooled together and kept at -80°C until sequencing.

Sequencing and data analysis

The pooled libraries were sequenced on an Illumina HiSeq 2500 next generation sequencing system at the UCLA Neurosciences Genomics core facility as 64 bp single-end reads using the custom sequencing primer pMargent3 and the standard Illumina sequencing primer (Table 2).

Data analysis was performed using the UCLA Galaxy platform [34–37]. Reads were cleaned by removal of ambiguous nucleotides, adapters, and primer sequences. The reads were filtered for length and quality: reads fewer than 20 nucleotides long or with a quality score of 20 or less for 95% of the cycles were eliminated.

The remaining reads were mapped to the *L. interrogans* serovar Copenhageni strain Fiocruz L1-130 genome using Bowtie [38]. The resulting file was sorted to obtain a list of insertion sites, their corresponding gene numbers, and the number of reads per insertion site. In this way, the frequency with which each mutant occurred in each tissue and each animal was determined. Output/input ratios for each mutant were calculated by dividing a mutant's output frequency by its frequency in the input pool.

Statistics

Output/input ratios across the 42 mutants were normalized by setting the median ratio for each animal to 1.0. Ratios were compared to 1.0 (neutral fitness) using the Wilcoxon rank test with P values < 0.05 considered statistically significant. Comparison of ratios between duplicates was performed using the Student's t-test with P values < 0.05 considered statistically significant.

Correlations between the number of mapped reads and the load of bacteria in blood, kidney or liver were analyzed by the Pearson correlation test. Reproducibility of the Tn-Seq experiment was assessed using the Spearman correlation coefficient. Comparison of survival curves was performed using the Mantel-Cox log rank test. Comparison of motility (diameter of growth) between strains was performed using the Student's t test with P values < 0.05 considered statistically significant. For all statistical tests, the number of asterisks indicates the significance level; * P < 0.05, ** P < 0.01 and *** P < 0.001.

Quantification of the bacterial load in tissues by qPCR

The number of bacteria in each sample (Input pool, serum, kidney and liver) was quantified with the Bio-Rad iQ5 real time system using the iTaq universal probe supermix. The *lipL32* gene was amplified using the LipL32-45F and LipL32-286R primers and the LipL32-189P probe as previously described [30, 39] (Table 2). The PCR mixture contained 250 nM of each primer, 150 nM of the specific probe, and 5 μ l of DNA in a total volume of 20 μ l. The amplification protocol consisted of 10 min at 95°C, followed by 40 cycles of amplification (95°C for 15 s and 60°C for 1 min). A negative result was assigned where no amplification occurred or if the threshold cycle (CT) was greater than 36. Real-time PCR was performed in duplicate for each sample. Results were expressed as the number of leptospires/g of tissue used for DNA extraction or number of leptospires/mL of serum or culture.

Western Blots

loa22::Tn, *flaA1*::Tn, *ligB*::Tn and *lic20111*::Tn and the WT strain were grown at 30°C in EMJH, supplemented with Km when necessary, to an OD_{420nm} of ≈ 0.2 . Half of the *ligB* mutant and WT cultures were incubated with 120 mM NaCl for 4 hours at 30°C to maximize *ligB* expression [40].

Samples were separated on a 4–12% gradient NuPAGE Bis Tris precast gel (Invitrogen) and transferred to a PVDF membrane (Millipore) by semi-dry transfer at 25 V for 45 min with a Bio-Rad Trans-blot Semi-dry Transfer Cell unit.

Membranes containing the *loa22* mutant were probed with a 1/1,000 dilution of Loa22 rabbit polyclonal antiserum [41] and a 1/10,000 dilution of LipL41 rabbit polyclonal antiserum [42]. Membranes containing the *flaA1* mutant were incubated with FlaA1 rabbit polyclonal antiserum at the dilution of 1/2,000 [43] and ImpL63 polyclonal antiserum at the dilution of 1/ 5,000 [44]. Membranes containing *ligB* mutant or *lic20111* mutant were probed with mixture of a 1/2,000 dilution of LigAB rabbit polyclonal antiserum [45] and a 1/10,000 dilution of LipL41 rabbit polyclonal antiserum as a loading control. All membranes were then incubated in 1/5,000 dilution of horseradish peroxidase-conjugated donkey anti-rabbit immunoglobulin G (Amersham) and developed by enhanced chemiluminescence (Pierce ECL reagent, Pierce).

Motility assay

The motility of the *flaA1* and *lic20111* mutants in liquid EMJH+Km medium was analyzed by dark field microscopy and compared to the motility of the WT strain. Motility was also evaluated by spotting 0.5% agar semi-solid EMJH plates with 5 μ l of four different cultures of the same mutant grown at the OD_{420nm} of 0.2. Plates were incubated for 15 days at 30°C, and diameters of growth were measured. Assays were performed in triplicate.

Growth curves

The *lic12327a*, *lic12327b*, *lic20111*, *loa22*, *ligB* and *flaA1* mutants and WT strain were cultured at 30°C in EMJH, supplemented with Km as appropriate. Growth was monitored daily by measurements of the optical density at 420 nm on a Pharmacia Ultrospec 2000 spectrophotometer. At least three independent growth curves were performed for each mutant and strain.

RNA extraction and genes expression

The *lic20111* mutant and WT strain were grown at 30°C to an OD_{420nm} of ≈ 0.3 . Strains were cultured in duplicate. RNA was extracted from 20 mL of culture with Trizol reagent (Invitrogen) according to the manufacturer's guidelines. Contaminating DNA was removed from RNA preparations using Turbo DNase from Ambion, and RNA was subsequently purified using the RNeasy kit (Qiagen, Valencia, CA). 1 µg of each RNA sample was converted into cDNA with iScript Reverse Transcriptase Supermix (Bio-Rad) following the manufacturer's instructions. The amounts of specific cDNA were determined by quantitative PCR using the Bio-Rad iQ5 real time system with the iQ SYBR Green Supermix as described [46]. Primer sequences are shown in Table 2. The amount of cDNA of interest measured in each PCR assay was normalized to the amount of *rpoB* cDNA or *flaB* cDNA. The fold change of each gene was determined by the 2^{- $\Delta\Delta$ Ct} method [47].

Results

Selection of the mutants

We created a library of over 800 *Himar1* transposon mutants in *L. interrogans* serovar Manilae strain L495. The insertion site in each mutant was determined individually by sequencing nested PCR products obtained by amplifying across one end of the transposon, as previously described by Slamti *et al.* [28].

An input pool of 42 mutants with insertions in 33 ORFs and 6 intergenic regions (Table 1) was selected to validate the Tn-Seq approach and to examine changes in the composition of the mutant population across various tissues during infection. For validation of the Tn-Seq approach, the input pool included control mutants with transposon insertions in genes that have been tested for virulence in a rodent model of lethal leptospirosis. Insertional mutations previously shown to attenuate virulence occurred in *loa22*, encoding a protein with an OmpA domain, and *lic20111/lb139*, encoding a potential phosphatase that may modulate a two-partner switch mechanism controlling an alternative sigma subunit [11, 12]. We also included mutants with insertions in genes previously shown to not be required for virulence including the adhesin gene *ligB* and the flagellar gene *flaA1* [13, 48]. Six intergenic mutants were included that harbored the transposon between open reading frames.

To identify novel *L. interrogans* genes required for *in vivo* fitness, the pool included 23 mutants with insertions in 20 genes encoding putative signal transduction proteins. Our rationale for focusing on this gene category was that disruptions of signaling genes would be more likely to affect *in vivo* fitness due to their potential downstream effects on multiple functions. The input pool included two mutants with insertions in *lic12324* encoding a gene containing a phosphatase domain, seven mutants with insertions in adenylate/guanylate cyclase genes, three in diguanylate cyclase or phosphodiesterase genes, five in histidine kinase genes, one in a gene encoding a member of the AcrR family of transcriptional regulators, and one in a gene encoding an alternative sigma factor (Table 1). The *lic12324*, *lic12327* and *lic12627* genes were each represented by two mutants with insertions in different locations within the same open reading frame. We also selected ten additional mutants with potential roles in *in vivo* fitness, including mutants with insertions in *lolD*, encoding a homolog of the ATPase component of the lipoprotein export system, a heme oxygenase and the flagellar gene *flaB2* (Table 1).

The Tn-Seq experiment

Eight hamsters were challenged with the pool of 42 mutants. Four days post-challenge, blood, kidney and liver were collected. DNA extracted from these tissues and the input pool were analyzed by Illumina sequencing. 2×10^4 – 3×10^6 reads were obtained for each organ (S1 Table). On average approximately 25% of the reads were discarded from the analysis during the cleaning phase of the sequence analysis. The remaining reads were mapped to the high-quality sequence of the Fiocruz L1-130 genome using Bowtie (in the Galaxy software), and the frequency of each mutant within the bacterial population in each tissue and in each animal was determined. The nucleotide sequence of the Corresponding ORFs in the Fiocruz L1-130 strain.

To examine the reproducibility of our Tn-Seq protocol (sample preparation and sequencing), technical replicates with the input pool DNA were performed. Two sequencing libraries were created from the DNA with two different indexing primers. A strong correlation ($r^2 = 0.9992$) was observed between the composition of the population of mutants of these libraries (Fig 1), demonstrating the reproducibility of the amplification and sequencing methods.



Fig 1. Reproducibility of the Tn-Seq experiment. We amplified the input pool DNA with two different indexing primers and sequenced both libraries with the Illumina HiSeq 2500 platform. Both sets of reads were processed as independent samples. We compared the percentage of each mutant obtained for both libraries and determined the correlation coefficient between the two libraries ($r^2 = 0.9992$).

The same DNA preparations used for Tn-Seq were also used to quantify the total number of bacteria in each sample by TaqMan qPCR targeting the *lipL32* gene. The results were expressed in terms of number of leptospires per gram of tissue or mL of serum (S1 Table). The leptospiral load in the liver, ranging from 3×10^4 /g to 2×10^8 /g, was always higher than in the kidneys, where it ranged from 2×10^4 /g to 1×10^7 /g. In serum, the number of leptospires was lower: 1×10^4 /mL to 3×10^5 /mL.

A significant positive correlation was found between the number of reads mapped and the burden of leptospires: $r^2 = 0.7963$ (P = 0.0029), $r^2 = 0.7818$ (P = 0.0036) and $r^2 = 0.9068$ (P = 0.0003) in blood, kidney and liver, respectively (Fig 2A-2C).

Changes in the composition of the population of mutants at 4 days postchallenge

Four days post-challenge, the composition of the population of mutants was quantified in blood, kidney and liver and was compared to that of the inoculum. The frequency of all mutants in the input pool was calculated, as well as their frequencies in each tissue and animal. The frequency of each mutant in the input pool ranged from 0.4% to 7% (S2 Table). All mutants were detected in all tissues with changes in the composition of the populations. The means of the percentages in blood, kidney and liver ranged from 0.2% to 8%, 0.2% to 9% and 0.2% to 13%, respectively (S2 Table).

For each mutant, we calculated the output/input ratio, defined as the frequency of a mutant in the blood, kidney or liver divided by its frequency in the input pool. The output/input ratios across the 42 mutants were normalized to a median ratio to 1.0 in each animal. For each mutant and each tissue, we determined the median of the normalized ratios of the eight



Fig 2. Relationship between the number of mapped reads and the bacterial load. Correlation between the log of the total number of mapped reads and the log of the number of bacteria (A) in blood, (B) kidney and (C) liver. In all tissues, there is a significant correlation between the number of reads and the number of bacteria, $r^2 = 0.7963$ (P = 0.0029), $r^2 = 0.7818$ (P = 0.0036) and $r^2 = 0.9068$ (P = 0.0003) in blood, kidney and liver, respectively.

doi:10.1371/journal.pntd.0005117.g002

animals and compared it to 1.0 using the Wilcoxon signed-rank test. A fitness value of 1.0 is neutral, less than 1.0 is disadvantageous and greater than 1.0 is advantageous [49]. We observed statistically significant changes in fitness for 21, 15 and 24 mutants in blood, kidney and liver, respectively (Fig 3A–3C and S3 Table). In all tissues, eleven mutants had fitness values higher than 1.0. In contrast, ten, four and thirteen mutants had decreased fitness in the blood, kidney and liver, respectively. A total of 12 mutants had statistically significant changes in all three tissues; with either decreased (e.g., the *lic12327* and *lic10203* mutants) or increased (e.g., the *lic12506* and *lic13004* mutants) fitness.

Control mutants

In addition to the Tn-Seq results (Fig 4), we conducted Western blots (Fig 5), motility assays (Fig 6) and growth curve analysis (Fig 7) to confirm previously described phenotypes of the control mutants. To determine whether the virulence of the control mutants was as observed in previous studies, we assessed their virulence in a survival experiment (Fig 8 and S4 Table) and examined kidney colonization. Growth curves showed that none of the control mutants exhibited a defect in *in vitro* growth compared to the WT strain (Fig 7).

loa22 mutant. At four days post-challenge, the fitness of the *loa22* mutant was decreased in all tissues (P = 0.0078 for both blood and liver) (Fig 4A and S3 Table). Immunoblots confirmed the lack of production of Loa22 in the *loa22* mutant. The protein was only detected in the WT strain (Fig 5A). We also confirmed the virulence phenotype by challenging groups of 6 hamsters with 10⁶ *loa22* mutant or with the WT. All animals infected with the WT strain died between 5 to 8 days post infection whereas only 3 hamsters challenged with *loa22* mutant met the endpoint criteria (P = 0.0046; Fig 8 and S4 Table). All kidneys cultured from animals infected with the WT strain or *loa22* mutant were culture positive in EMJH.

ligB mutant. In the Tn-Seq experiment, the fitness of the *ligB* mutant was not affected (Fig 4B and S3 Table) in any of the tissues. We confirmed by immunoblot (Fig 5B) that the *ligB* mutant did not produce LigB, whether or not the medium was supplemented with NaCl. Although LigB was not produced, LigA was produced by the *ligB* mutant. We challenged hamsters with 10^6 of the *ligB* mutant or WT strain and did not observe differences in survival (P = 0.5514; Fig 8 and S4 Table) and kidneys from all animals were culture positive.

flaA1 mutant. The fitness of *flaA1* mutant in the Tn-Seq experiment was significantly higher than 1.0 in blood and kidney (P = 0.0078; Fig 4C). Western blots with the *flaA1* mutant confirmed that the mutant did not produce FlaA1 (Fig 5C). Motility was decreased compared to the wild-type strain as observed in the darkfield microscope. The diameter of growth of the *flaA1* mutant on the motility plate was smaller than that of the wildtype (P = 0.0002; Fig 6A and 6B). We challenged hamsters with 10^6 *flaA1* mutant or the WT strain and we did not find any difference in survival (Fig 8 and S4 Table) and kidneys from all animals were culture positive.

lic20111 mutant. The fitness of the *lic20111* mutant was not affected in the Tn-Seq experiment (Fig 4D and S3 Table). Hamsters were challenged intraperitoneally with 10^6 WT or 10^6 *lic20111* mutants cells and monitored daily until they met the endpoint criteria or for 21 days. All animals infected with the WT strain or with *lic20111*.:Tn met the endpoint criteria within 5–8 days. The survival curves did not differ significantly between the strains (Fig 8 and S4



PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0005117 November 8, 2016

Fig 3. Fitness of 42 *L. interrogans* **mutants during acute infection of hamsters.** The 42 transposon mutants were grown independently, quantified, diluted at the concentration of 10^6 /mL and pooled together (input pool). Eight hamsters were challenged intraperitoneally with 1 mL of the pool of mutants. Four days post-challenge, animals were sacrificed, and blood, kidney and liver were collected (output pools). The frequency of each of the 42 mutants in the input pool and output pools was quantified using the Illumina HiSeq 2500. The output/input ratio was determined for each mutant in (A) blood, (B) kidney and (C) liver in each animal. Each ratio is represented by a white circle. For each mutant and each tissue, the median of ratios (red line) was determined and compared to 1.0 using the Wilcoxon rank test. The dotted line represents fitness of 1.0, which means no change in fitness. Mutants whose fitness is significantly affected are marked by asterisks: * P < 0.05; ** P < 0.01.

doi:10.1371/journal.pntd.0005117.g003

Table). The motility assay on 0.5% agar EMJH plates showed no difference in the diameter of growth of the *lic20111* mutant compared to the WT (Fig 6C and 6D). The *lic20111* mutant produced similar amounts of LigB and LigA as the wildtype (Fig 5D). We examined the transcript levels of the downstream genes in the *lic20111* mutant and the WT strain by qRT-PCR. When *rpoB* was used as the reference gene, the *lic20111* mutant exhibited 1.6-, 1.4- and 2.5-fold drops for *lic20110*, *lic20109* and *lic20108* RNA respectively, relative to wild-type strain. When *flaB* was used as the reference gene, the same transcripts in the *lic20111* mutant exhibited 1.1-, 0.9- and 1.6-fold reductions.

Pairs of mutants with transposon insertions in the same gene

In the pool of mutants used to challenge the animals, we included three pairs of mutants with different transposon insertion sites in the same gene: *lic12324*, *lic12327* and *lic12627*. The insertion sites in the *lic12324* gene were separated by 468 bp and by only 244 bp in the *lic12327* gene. In the *lic12627* gene insertions sites were farther apart (separated by 910 bp) (Fig 9A).

For the paired *lic12324* mutants and paired *lic12327* mutants, we observed a statistically significant decrease of *in vivo* fitness in both members of the pairs (Fig 9B–9E). When we compared *lic12324a*::Tn to *lic12324b*::Tn and *lic12327a*::Tn to *lic12327b*::Tn, we did not see any statistically significant differences in their fitness.

In the third pair of mutants, the fitness of the *lic12627a* mutant (insertion site in the 5' end of the gene) was reduced in liver and kidney but significantly only in liver (Fig 9F and 9G). However, the fitness of the *lic12627b* mutant (insertion site in the 3' end of the gene) was significantly higher than 1.0 in blood and liver. The comparison of the ratios of these two mutants confirmed statistically significant differences in kidney (P = 0.0379) and liver (P = 0.011).

Previously, expression of the *lic12327* gene has been shown to be upregulated by osmolarity [50], suggesting its role in dissemination and survival in the host. Because of the decrease in fitness in both *lic12327* mutants, we confirmed that neither mutant had a growth defect compared to the WT strain (Fig 7). We studied their virulence separately by challenging hamsters IP with 10^6 leptospires. Only one of six and two of six animals infected with *lic12327b* and *lic12327a* mutants, respectively, met endpoint criteria (survival curves statistically different from the WT, P = 0.0019 and P = 0.0051, respectively; Fig 8 and S4 Table). All animals had kidney colonization whether or not they met endpoint criteria.

Signal transduction genes

Twenty-three mutants with transposon insertions in putative signal transduction genes were included in this study (Table 1). Seven mutants did not present any change in any tissue. The sixteen other mutants exhibited *in vivo* fitness that differed significantly from 1.0: five mutants had changes in only one tissue, three in two tissues and eight in all three tissues (Fig 3 and S3 Table). Among the eight mutants with changes in fitness in all tissues, five presented an increase in their fitness whereas three showed a decrease (Fig 3).



Fig 4. Fitness of *L. interrogans* **control mutants during acute infection of hamsters.** In the pool of mutants used to challenge the animals, we included mutants whose virulence is known to be affected: (A) *loa22*::Tn and (D) *lic20111*::Tn or unaffected: (B) *ligB*::Tn and (C) *flaA1*::Tn. The output/input ratio of each mutant was determined for each animal in blood, kidney and liver. Each ratio is represented by a black diamond and the median of these ratios by a red line. The dotted line represents fitness of 1.0, which means neutral fitness. The median was compared to 1 using the Wilcoxon rank test. The number of asterisks indicates the significance level: * P < 0.05.

The five mutants with an increase in their fitness in all tissues had transposon insertions in adenylate or guanylate cyclase genes (*lic12506*::Tn, *lic12670*::Tn and *lic13004*::Tn), in a histidine kinase gene (*lic11432*::Tn) or in a transcriptional regulator gene (*lic13073*::Tn) (Fig 3 and S3 Table). The three mutants with decreased fitness in all tissues had transposon insertions in an



Fig 5. Western blots of *L. interrogans* **control mutants.** (A) Analysis of *loa22* expression by Western blotting of the *loa22* mutant and the WT strain. Blots were probed with anti Loa22 antisera. (B-D) Western blot of LigA and LigB expression in the *lic20111* mutant, *ligB* mutant and the WT strain, supplemented (+) or not (-) with 120 mM sodium chloride. Whole-cell lysates were analyzed by immunoblotting with anti-Ligs antiserum. (C) Analysis of *flaA1* expression by immunoblotting in the *flaA1* mutant and the wildtype strain (WT). Detection was performed with anti FlaA1 antisera. Anti-ImpL63 and anti-LipL41 antisera were used as a loading control. Positions of molecular mass standards are shown in kilodaltons.



Fig 6. Motility assay of *L. interrogans* control mutants. 0.5% agar EMJH plates were spotted with the wild type strain and four different cultures of (A) the *flaA1* mutant or (C) the *lic20111* mutant. (B-D) Growth diameter of each strain was measured after two weeks incubation at 30°C. Three independent experiments were performed. A representative plate is shown from one of them.

doi:10.1371/journal.pntd.0005117.g006



Fig 7. Growth curves of selected *L. interrogans* mutants. The *loa22*::Tn (light blue), *ligB*::Tn (pink), *flaA1*::Tn (green), *lic20111*::Tn (orange), *lic12327a*::Tn (red), *lic12327b*::Tn (purple) and the WT (dark blue) strain were cultured at 30°C in EMJH, supplemented with Km as appropriate. Growth was monitored by measuring the OD_{420nm}. No defect in growth was observed for any of the strains. Data are representative of those from three independent experiments.

adenylate or guanylate cyclase gene (*lic12327a*::Tn and *lic12327b*::Tn) or in a phosphatase gene (*lic12324a*::Tn) (Fig 3 and S3 Table).

Non signal transduction genes

Thirteen mutants with transposon insertions in non-signaling genes were included in the pool of mutants (Fig 3 and S3 Table). Three of these were "control" mutants and their behavior has been described above. Among the ten other mutants, *lic11889*::Tn, which has a transposon inserted in a flagellar protein, had increased fitness in all tissues and *lic10203*::Tn, which has an insertion in an epimerase gene, had diminished fitness. The fitness of the eight remaining mutants was not affected in any tissue.

Intergenic regions

Six mutants with transposon insertions in intergenic regions were included in the input pool. Only one (*inter20138*::Tn) did not exhibit a change in fitness; two mutants (*inter10855*::Tn and *inter13722*::Tn) had increased in fitness in all tissues (Fig 3 and S3 Table). The three other mutants showed decreased fitness in blood and liver.

Distribution of mutant fitness values in each animal

The distribution of the fitness values of the mutants differed among animals. We identified two types of distribution: a narrow distribution where all mutants have output/input ratios ranging from less than 2.5 log and a broad distribution where the range of ratios varies from more than 2.5 log (S2 Fig). In blood and kidney, these two distributions are observed in the same animals: narrow distribution in animals 3, 5, 6 and 7, broad distribution in animals 1, 2, 4 and 8 (S2A)



Fig 8. Survival experiment of hamsters infected with individual *L. interrogans* **mutants.** Hamsters were challenged IP with 10^{6} WT (dark blue), *loa22*::Tn (light blue), *ligB*::Tn (pink), *flaA1*::Tn (green), *lic20111*::Tn (orange), *lic12327a*::Tn (red) or *lic12327b*::Tn (purple) and were monitored for 28 days or until they met endpoint criteria. All animals infected with the WT strain, *ligB*::Tn and *lic20111*::Tn met the endpoint criteria in 5 to 8 days (*ligB*::Tn and *lic20111*::Tn survival curves not statistically different to the WT, P = 0.5514 and P = 0.1557, respectively). One animal challenged with *flaA1*::Tn survived, but the survival curve statistically different from the WT (P = 0.4364). Three hamsters infected with *loa22*::Tn met the endpoint criteria in 6 to 9 days, survival curve statistically different from the WT (P = 0.0046). Two animals challenged with *lic12327a*::Tn and one with the *lic12327b* mutant met the endpoint criteria in 7 days. Both *lic12327* mutants showed a statistically different survival curve than the WT, P = 0.0051 and P = 0.019 respectively.

and S2B Fig). In liver, only two animals have a narrow distribution, animal 3 and animal 7 (S2C Fig).

Discussion

We have developed a Tn-Seq assay to identify *L. interrogans* virulence genes candidates. The combination of transposon mutagenesis with the power of high-throughput sequencing successfully detected mutants with *in vivo* fitness defects. A major advantage of Tn-Seq is the ability to screen a large pool of mutants for altered *in vivo* fitness with a limited number of animals. This approach allowed us to reduce the cost of such an extensive screening of mutants, first by using a small number of animals and second by performing high throughput sequencing in a single lane in the Illumina system. Our findings with a small number of mutants suggest that Tn-Seq can be used as a first step to identify virulence genes of *L. interrogans* by screening large pools of mutants for defects in *in vivo* fitness. However, because not all *L. interrogans* mutants with diminished fitness within a pool of mutants will be attenuated in virulence [15], experiments with larger numbers of mutants need to be done to better understand the relationship between fitness and virulence.

This was the first Tn-Seq experiment performed with leptospiral mutants to assess their *in vivo* fitness. Due to the high bacterial tissue load, we were able to obtain sequencing reads from the DNA extracted directly from blood, kidney and liver. A culture step prior to DNA extraction was not necessary and allowed us to avoid *in vitro* growth bias. However, the approach can overestimate the relative abundance of a mutant by measuring the DNA from dead



Fig 9. Pairs of mutants with transposon insertions in the same gene. (A) Locations of transposon insertion sites. In the pool of mutants used to challenge the animals, we included three pairs of mutants that have insertion sites at different locations in the same gene. The location of both transposon insertions is designated by black arrows in each of the following genes: *lic12324* (insertion sites: 2806250 and 2806718 in the Fiocruz L1-130 genome), *lic12327* (insertion sites: 2810027 and 2810271) and *lic12627* (insertion sites: 3177595 and 3178505). (B-G) Fitness of each pair of mutants. The output/input ratios for each of the eight animals were determined for each mutant in blood, kidney and liver. Each ratio is represented by a black diamonds and the median of these ratios by a red line. The dotted line represents fitness of 1.0, which means neutral fitness. The median was compared to 1.0 using the Wilcoxon rank test. The number of asterisks indicates the significance level: * P < 0.05. No statistically significant differences were observed between the pair of *lic12327* mutants or between the *lic12324* mutants for any tissue. The comparison of the ratios of these two *lic12627* mutants confirmed statistically significant differences in kidney (P = 0.0379) and liver (P = 0.0011).

doi:10.1371/journal.pntd.0005117.g009

bacteria. We expect the contribution from dead leptospires to be minimal due to the exponential growth of the bacteria in tissues during the four days of infection [39].

We demonstrated the reproducibility of our protocol by processing the input pool DNA with two different indexing primers and comparing the frequency of each mutant obtained in both libraries (Fig 1). A strong correlation was observed between these libraries, demonstrating the reproducibility of our protocol (PCR and sequencing). To validate Tn-Seq as a method to identify virulence genes of L. interrogans and to examine the relationship of fitness to virulence, the input pool included mutants with insertions in genes whose virulence had been examined in earlier studies. Transposon insertions in *loa22* and *lic20111* attenuated virulence [11, 12], whereas a transposon insertion in *flaA1* and a targeted deletion of *ligB* had no effect [13, 48]. In our experiments, no defect in fitness of either the *ligB* or *flaA1* mutant was observed in any of the tissues tested (Fig 4B and 4C) and, as previously described, no attenuation in their virulence compared to the WT strain was seen in the hamster model (Fig 8). The loa22 mutant exhibited a decrease in *in vivo* fitness in blood and liver (Fig 4A) and attenuation in its virulence in the animal model (Fig 8). These results confirm previous studies showing a role for *loa22* in virulence [11]. The partial virulence attenuation of the loa22 mutant differed from the findings of the study by Ristow *et al.*, in which the mutant was completely avirulent [11]. This difference may be related to the different parent strain: in our study, the loa22 mutant was generated in the highly virulent L495 strain $(LD_{50} < 10^2)$ [51] whereas it was previously obtained in the less virulent Lai strain 56601 ($LD_{50} > 10^7$) [11].

Surprisingly, neither the in vivo fitness (Fig 4D) nor the virulence (Fig 8) of the lic20111 mutant was affected, in contrast to the phenotype of another *lic20111* mutant described in an earlier study [12]. The *in vitro* phenotype of our *lic20111* mutant was similar to the WT in its motility (Fig 6C and 6D), Lig protein production (Fig 5D) and growth (Fig 7), which is in opposition to the loss of virulence, reduction in motility, and diminished *lig* transcript production observed with an lic20111 mutant described by Eshghi et al. In that study, it was proposed that *lic20111* is the first gene of a five-gene operon and that the insertion of the transposon in *lic20111* caused attenuation of its virulence in the hamster model by polar effects on downstream transcription, which was verified by qRT-PCR [12]. We also observed diminished transcription of the downstream genes with our *lic20111* mutant, although the effect was weak. The transposon is inserted in different locations in the *lic20111* mutants: at the 3' end of the gene in the Eshghi et al. study and near the middle of the gene in our study (S1 Fig). The difference in virulence, motility, and lig expression between the two lic20111 mutants suggests that the location of the transposon within a gene may influence the mutant's phenotype. By extension, the difference in in vivo fitness observed between the two lic12627 mutants (Fig 9F) may be explained by the different insertion sites of the transposon (Fig 9A). This would suggest that the nearly full length LIC12627 protein generated from the lic12627b mutant, which harbors the transposon close to the 3' end of *lic12327*, retains adequate function to maintain the fitness

of the strain. Although we lack experimental data that confirms expression of an active gene product from the *lic12627b* mutant, a similar effect was proposed by Lin *et al.*, [18, 52], who noted that in their collection of 4,479 transposon insertion mutants in *B. burgdorferi*, insertions in the last 10% of ORFs were over-represented.

Five of the mutants included in our study have been studied previously in the experiment reported by Marcsisin *et al.* [15], in which each animal was inoculated with a pool of 10 mutants. Similar results were obtained with some of our mutants. For instance, the *lic12324* mutant, whose *in vivo* fitness was decreased in all tissues in our study, was detected by standard PCR in kidney and blood from only one and two animals out of five, respectively, in Marcsisin's study. Comparable results were obtained in both studies with the *lic13274* mutant, which was detected from four out of five animals in Marcsisin's study and for which no change in fitness was observed in our Tn-Seq experiment. In contrast, while we observed no change or an increase in *in vivo* fitness of our *lic20182* and *lic10641* mutants (Fig 3A–3C), these mutants could not be detected in blood and kidney (except in the blood of one animal with *lic10641*:: Tn) in Marcsisin's study [15]. These differences could result from differences in the inoculation dose, time of infection, or an unrecognized shortcoming with our assay.

We identified two *lic12327* mutants with reduced *in vivo* fitness in blood, kidney and liver (Fig 9D and 9E). *lic12327* encodes a putative adenylate/guanylate cyclase that contains a GAF domain and an adenylate/guanylate cyclase catalytic domain. This gene has been shown to be upregulated by physiological osmolarity [50] suggesting a role during host infection. The transposon insertion sites are 244 nucleotides apart from each other in these two mutants but both are located in the GAF domain. Both mutants were attenuated for virulence when tested individually in the hamster model (Fig 8 and S4 Table) and were recovered from kidneys. Experiments from another study demonstrated that a putative adenylate cyclase secreted from *L. interrogans* (LA4008/LIC13201) elevated cAMP levels in a human monocytic cell line [53]. These observations suggest that cyclic nucleotides produced by *L. interrogans* play a variety of roles during infection.

In contrast, we observed an increase in fitness for several mutants. The advantage of losing functional genes has been observed with *Salmonella enterica*, in which 25% of spontaneous deletions caused by randomly-inserted transposons caused enhanced growth rates under at least one of three growth conditions [54]. The enhanced fitness of mutants could be explained in part by the reduced metabolic burden in mutants that no longer synthesize proteins that are not essential for growth [54]. Alternatively, the functions provided by the disrupted genes may be provided by nearby mutants in the pool through the production of extracellular "common goods" [55]. For example, an inactivating mutation in the *Pseudomonas aeruginosa* gene encoding the quorum sensing regulator LasR results in the mutant out-competing the wild-type strain during co-culture [56]. Because signaling proteins are more likely that structural proteins to affect expression of multiple genes, our pool of mutants may be enriched for those with increase fitness *in vivo*.

In addition to the control mutants that have previously been described, we included intergenic mutants in the input pool as potential controls for neutral effects on *in vivo* fitness. Surprisingly, only one out of six intergenic mutants was unaffected in fitness. Two of the intergenic mutants had an increase in fitness and three others exhibited a decrease (Fig 3A– 3C). These unexpected results can be due to the insertion of the transposon into a small RNA gene, into a promoter, regulatory or transcriptional terminator region, or into a protein-coding gene that has not been annotated. None of the small RNA genes identified in Camaino *et al*.'s RNA-seq study were disrupted in our set of mutants [57].

Nevertheless, there are several general limitations to Tn-Seq that need to be considered. A decrease in fitness might be due to a mutant being out-competed by the other mutants in the

pool rather than a direct effect of the transposon insertion on fitness [58, 59]. An absence of change in *in vivo* fitness of a mutant that otherwise would have poor fitness in individual infections could be due to cooperation between mutants [60, 61]. Indeed, 325 exoproteins have been identified in *L. interrogans* cultured under conditions mimicking infection [62]. Therefore, a mutant that fails to produce one of these exoproteins could be complemented intercellularly by another mutant. Additionally, bottlenecks during infection may impede recovery of random mutants from the original pool. However, all mutants from the input pool were recovered in all three tissues suggesting that bottlenecks did not significantly affect our experiment. Nevertheless, increasing the size of the pool may cause the stochastic loss of mutants during infection. This can be minimized by increasing the size of the inoculum [17]. Despite these limitations, we anticipate that Tn-Seq can be used to screen larger pools of *L. interrogans* mutants in a limited number of animals.

Supporting Information

S1 Table. Number of reads mapped to the Fiocruz L1-130 genome and number of genome equivalents (Geq) per milliliter of serum or gram of kidney and liver. (DOCX)

S2 Table. Frequencies of each mutant in the input pool, in blood, kidney and liver of each animal.Mean of the frequencies per mutants and standard deviation. (DOCX)

S3 Table. Output/input ratios of each mutant frequencies in each animal in blood, kidney and liver. Median of ratios and variance per mutant. (DOCX)

S4 Table. Survival experiment with selected mutants. (DOCX)

S1 Fig. Insertion sites of the transposon in *loa22, flaA1, ligB* and *lic20111*. The red arrow represents the insertion site in this study and the grey one in previously described studies: Ristow *et al.* [11], Lambert *et al.* [48] and Esghi *et al.* [12], for *loa22*::Tn, *flaA1*::Tn and *lic20111*:: Tn respectively. The gray zone in *ligB* gene shows the part of the gene that was removed in Croda *et al.* study [13]. (TIFF)

S2 Fig. Fitness distribution of mutants in each animal. The output/input ratio of each mutant was determined for each animal in (A) blood, (B) kidney and (C) liver. The ratio of each mutant is represented by a black diamonds and the median of these ratios by a red line. (TIFF)

Acknowledgments

The authors thank Linden Hu, Erin Troy and Meghan Ramsey for helpful discussions regarding Illumina sequence data analysis. The authors also thank Karen Evangelista for her technical assistance with the animal experiments and Jane Babbitt for critical reading of the manuscript.

Author Contributions

Conceptualization: KL JM DAH.

Data curation: KL JM.

Formal analysis: KL JM DAH.

Funding acquisition: DAH.

Investigation: KL JM.

Methodology: KL JM.

Project administration: DAH.

Resources: KL JM.

Software: KL JM.

Supervision: KL JM DAH.

Validation: KL JM.

Visualization: KL JM.

Writing – original draft: KL JM.

Writing - review & editing: KL JM DAH.

References

- 1. Levett PN. Leptospirosis. Clin Microbiol Rev. 2001; 14(2):296–326. doi: 10.1128/CMR.14.2.296-326. 2001 PMID: 11292640
- Sarkar U, Nascimento SF, Barbosa R, Martins R, Nuevo H, Kalofonos I, et al. Population-based casecontrol investigation of risk factors for leptospirosis during an urban epidemic. Am J Trop Med Hyg. 2002; 66(5):605–10. PMID: 12201599
- Tassinari WS, Pellegrini DC, Sa CB, Reis RB, Ko AI, Carvalho MS. Detection and modelling of case clusters for urban leptospirosis. Trop Med Int Health. 2008; 13(4):503–12. doi: <u>10.1111/j.1365-3156</u>. 2008.02028.x PMID: 18312472
- Ko AI, Galvao Reis M, Ribeiro Dourado CM, Johnson WD Jr., Riley LW, Salvador Leptospirosis Study Group. Urban epidemic of severe leptospirosis in Brazil. Lancet. 1999; 354(9181):820–5. PMID: 10485724
- Costa F, Hagan JE, Calcagno J, Kane M, Torgerson P, Martinez-Silveira MS, et al. Global morbidity and mortality of leptospirosis: a systematic review. PLoS Negl Trop Dis. 2015; 9(9):e0003898. doi: 10. 1371/journal.pntd.0003898 PMID: 26379143
- Adler B. Pathogenesis of leptospirosis: cellular and molecular aspects. Vet Microbiol. 2014; 172(3– 4):353–8. doi: 10.1016/j.vetmic.2014.06.015 PMID: 24999234
- McBride AJ, Athanazio DA, Reis MG, Ko AI. Leptospirosis. Curr Opin Infect Dis. 2005; 18(5):376–86. PMID: 16148523
- Fouts DE, Matthias MA, Adhikarla H, Adler B, Amorim-Santos L, Berg DE, et al. What makes a bacterial species pathogenic?: Comparative genomic analysis of the genus *Leptospira*. PLoS Negl Trop Dis. 2016; 10(2):e0004403. doi: 10.1371/journal.pntd.0004403 PMID: 26890609
- Adler B, Lo M, Seemann T, Murray GL. Pathogenesis of leptospirosis: the influence of genomics. Vet Microbiol. 2011; 153(1–2):73–81. doi: 10.1016/j.vetmic.2011.02.055 PMID: 21440384
- Murray GL, Morel V, Cerqueira GM, Croda J, Srikram A, Henry R, et al. Genome-wide transposon mutagenesis in pathogenic *Leptospira* species. Infect Immun. 2009; 77(2):810–6. doi: 10.1128/IAI. 01293-08 PMID: 19047402
- 11. Ristow P, Bourhy P, da Cruz McBride FW, Figueira CP, Huerre M, Ave P, et al. The OmpA-like protein Loa22 is essential for leptospiral virulence. PLoS Pathog. 2007; 3(7).
- Eshghi A, Becam J, Lambert A, Sismeiro O, Dillies MA, Jagla B, et al. A putative regulatory genetic locus modulates virulence in the pathogen *Leptospira interrogans*. Infect Immun. 2014; 82(6):2542– 52. doi: 10.1128/IAI.01803-14 PMID: 24686063
- Croda J, Figueira CP, Wunder EA Jr., Santos CS, Reis MG, Ko AI, et al. Targeted mutagenesis in pathogenic *Leptospira* species: disruption of the LigB gene does not affect virulence in animal models of leptospirosis. Infect Immun. 2008; 76(12):5826–33. doi: 10.1128/IAI.00989-08 PMID: 18809657

- Pappas CJ, Picardeau M. Control of gene expression in *Leptospira spp.* by transcription activator-like effectors demonstrates a potential role for LigA and LigB in *Leptospira interrogans* virulence. Appl Environ Microbiol. 2015; 81(22):7888–92. doi: 10.1128/AEM.02202-15 PMID: 26341206
- Marcsisin RA, Bartpho T, Bulach DM, Srikram A, Sermswan RW, Adler B, et al. Use of a high-throughput screen to identify *Leptospira* mutants unable to colonize the carrier host or cause disease in the acute model of infection. J Med Microbiol. 2013; 62(Pt 10):1601–8. doi: <u>10.1099/jmm.0.058586-0</u> PMID: 23813276
- van Opijnen T, Bodi KL, Camilli A. Tn-seq: high-throughput parallel sequencing for fitness and genetic interaction studies in microorganisms. Nat Methods. 2009; 6(10):767–72. doi: <u>10.1038/nmeth.1377</u> PMID: <u>19767758</u>
- van Opijnen T, Lazinski DW, Camilli A. Genome-wide fitness and genetic interactions determined by Tn-seq, a high-throughput massively parallel sequencing method for microorganisms. Curr Protoc Mol Biol / edited by Frederick M Ausubel [et al]. 2014; 106:7 16 1–7 24.
- Lin T, Troy EB, Hu LT, Gao L, Norris SJ. Transposon mutagenesis as an approach to improved understanding of *Borrelia* pathogenesis and biology. Front Cell Infect Microbiol. 2014; 4:63. doi: 10.3389/ fcimb.2014.00063 PMID: 24904839
- Gutierrez MG, Yoder-Himes DR, Warawa JM. Comprehensive identification of virulence factors required for respiratory melioidosis using Tn-seq mutagenesis. Front Cell Infect Microbiol. 2015; 5:78. doi: 10.3389/fcimb.2015.00078 PMID: 26583079
- Gawronski JD, Wong SM, Giannoukos G, Ward DV, Akerley BJ. Tracking insertion mutants within libraries by deep sequencing and a genome-wide screen for *Haemophilus* genes required in the lung. Proc Natl Acad Sci USA. 2009; 106(38):16422–7. doi: 10.1073/pnas.0906627106 PMID: 19805314
- Troy EB, Lin T, Gao L, Lazinski DW, Lundt M, Camilli A, et al. Global Tn-seq analysis of carbohydrate utilization and vertebrate infectivity of *Borrelia burgdorferi*. Mol Microbiol. 2016; 101(6):1003–23. doi: 10.1111/mmi.13437 PMID: 27279039
- Gallagher LA, Shendure J, Manoil C. Genome-scale identification of resistance functions in *Pseudo-monas aeruginosa* using Tn-seq. mBio. 2011; 2(1):e00315–10. doi: 10.1128/mBio.00315-10 PMID: 21253457
- Troy EB, Lin T, Gao L, Lazinski DW, Camilli A, Norris SJ, et al. Understanding barriers to *Borrelia burg-dorferi* dissemination during infection using massively parallel sequencing. Infect Immun. 2013; 81 (7):2347–57. doi: 10.1128/IAI.00266-13 PMID: 23608706
- 24. Ellinghausen HC Jr., McCullough WG. Nutrition of *Leptospira pomona* and growth of 13 other serotypes: Fractionation of oleic albumin complex and a medium of bovine albumin and polysorbate 80 Am J Vet Res. 1965; 26:45–51. PMID: 14266934
- 25. Johnson RC, Harris VG. Differentiation of pathogenic and saprophytic letospires. I. Growth at low temperatures. J Bacteriol. 1967; 94(1):27–31. PMID: 6027998
- 26. Demarre G, Guerout AM, Matsumoto-Mashimo C, Rowe-Magnus DA, Marliere P, Mazel D. A new family of mobilizable suicide plasmids based on broad host range R388 plasmid (IncW) and RP4 plasmid (IncPα) conjugative machineries and their cognate *Escherichia coli* host strains. Res Microbiol. 2005; 156(2):245–55. doi: 10.1016/j.resmic.2004.09.007 PMID: 15748991
- Picardeau M. Conjugative transfer between *Escherichia coli* and *Leptospira spp.* as a new genetic tool. Appl Environ Microbiol. 2008; 74(1):319–22. doi: 10.1128/AEM.02172-07 PMID: 17993560
- Slamti L, Picardeau M. Construction of a library of random mutants in the spirochete *Leptospira biflexa* using a mariner transposon. Methods Mol Biol. 2012; 859:169–76. doi: <u>10.1007/978-1-61779-603-6_9</u> PMID: 22367871
- Vallenet D, Engelen S, Mornico D, Cruveiller S, Fleury L, Lajus A, et al. MicroScope: a platform for microbial genome annotation and comparative genomics. Database (Oxford). 2009; 2009:bap021.
- Stoddard RA, Gee JE, Wilkins PP, McCaustland K, Hoffmaster AR. Detection of pathogenic *Leptospira* spp. through TaqMan polymerase chain reaction targeting the *lipL32* gene. Diagn Microbiol Infect Dis. 2009; 64(3):247–55. doi: 10.1016/j.diagmicrobio.2009.03.014 PMID: 19395218
- Lourdault K, Cerqueira GM, Wunder EA Jr., Picardeau M. Inactivation of *clpB* in the pathogen *Leptospira interrogans* reduces virulence and resistance to stress conditions. Infect Immun. 2011; 79 (9):3711–7. doi: 10.1128/IAI.05168-11 PMID: 21730091
- Lo M, Bulach DM, Powell DR, Haake DA, Matsunaga J, Paustian ML, et al. Effects of temperature on gene expression patterns in *Leptospira interrogans* serovar Lai as assessed by whole-genome microarrays. Infect Immun. 2006; 74(10):5848–59. doi: 10.1128/IAI.00755-06 PMID: 16988264
- Miller J. Spirochetes in body fluids and tissues: Manual of investigative methods. Springfield, IL: Charles C. Thomas Publisher; 1971. pp. 22–23.

- Giardine B, Riemer C, Hardison RC, Burhans R, Elnitski L, Shah P, et al. Galaxy: a platform for interactive large-scale genome analysis. Genome Res. 2005; 15(10):1451–5. doi: <u>10.1101/gr.4086505</u> PMID: 16169926
- Goecks J, Nekrutenko A, Taylor J, Galaxy T. Galaxy: a comprehensive approach for supporting accessible, reproducible, and transparent computational research in the life sciences. Genome Biol. 2010; 11(8):R86. doi: 10.1186/gb-2010-11-8-r86 PMID: 20738864
- **36.** Blankenberg D, Von Kuster G, Coraor N, Ananda G, Lazarus R, Mangan M, et al. Galaxy: a webbased genome analysis tool for experimentalists. Curr Protoc Mol Biol / edited by Frederick M Ausubel [et al]. 2010;Chapter 19:Unit 19 0 1–21.
- Afgan E, Baker D, van den Beek M, Blankenberg D, Bouvier D, Cech M, et al. The Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2016 update. Nucleic Acids Res. 2016;8; 44(W1):W3–W10. doi: 10.1093/nar/gkw343 PMID: 27137889
- Langmead B, Trapnell C, Pop M, Salzberg SL. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 2009; 10(3):R25. doi: <u>10.1186/gb-2009-10-3-r25</u> PMID: <u>19261174</u>
- Wunder EA Jr., Figueira CP, Santos GR, Lourdault K, Matthias MA, Vinetz JM, et al. Real-time PCR reveals rapid dissemination of *Leptospira interrogans* after intraperitoneal and conjunctival inoculation of hamsters. Infect Immun. 2016;23; 84(7):2105–15. doi: 10.1128/IAI.00094-16 PMID: 27141082
- 40. Narayanavari SA, Lourdault K, Sritharan M, Haake DA, Matsunaga J. Role of *sph2* gene regulation in hemolytic and sphingomyelinase activities produced by *Leptospira interrogans*. PLoS Negl Trop Dis. 2015; 9(8):e0003952. doi: 10.1371/journal.pntd.0003952 PMID: 26274394
- 41. Koizumi N, Watanabe H. Molecular cloning and characterization of a novel leptospiral lipoprotein with OmpA domain. FEMS Microbiol Lett. 2003; 226(2):215–9. PMID: 14553914
- Shang ES, Summers TA, Haake DA. Molecular cloning and sequence analysis of the gene encoding LipL41, a surface-exposed lipoprotein of pathogenic *Leptospira* species. Infect Immun. 1996; 64 (6):2322–30. PMID: 8675344
- **43.** Cullen PA, Xu X, Matsunaga J, Sanchez Y, Ko AI, Haake DA, et al. Surfaceome of *Leptospira spp.* Infect Immun. 2005; 73(8):4853–63. doi: 10.1128/IAI.73.8.4853-4863.2005 PMID: 16040999
- Haake DA, Matsunaga J. Characterization of the leptospiral outer membrane and description of three novel leptospiral membrane proteins. Infect Immun. 2002; 70(9):4936–45. doi: <u>10.1128/IAI.70.9.4936-4945.2002</u> PMID: 12183539
- **45.** Matsunaga J, Barocchi MA, Croda J, Young TA, Sanchez Y, Siqueira I, et al. Pathogenic *Leptospira* species express surface-exposed proteins belonging to the bacterial immunoglobulin superfamily. Mol Microbiol. 2003; 49(4):929–46. doi: 10.1046/j.1365-2958.2003.03619.x PMID: 12890019
- 46. Matsunaga J, Coutinho ML. Positive regulation of *Leptospira interrogans kdp* expression by KdpE as demonstrated with a novel β-galactosidase reporter in *Leptospira biflexa*. Appl Environ Microbiol. 2012; 78(16):5699–707. doi: 10.1128/AEM.00713-12 PMID: 22685146
- Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2^{-ΔΔCT} Method. Methods. 2001; 25(4):402–8. doi: 10.1006/meth.2001.1262 PMID: 11846609
- Lambert A, Picardeau M, Haake DA, Sermswan RW, Srikram A, Adler B, et al. FlaA proteins in *Leptospira interrogans* are essential for motility and virulence but are not required for formation of the flagellum sheath. Infect Immun. 2012; 80(6):2019–25. doi: 10.1128/IAI.00131-12 PMID: 22451522
- Kamp HD, Patimalla-Dipali B, Lazinski DW, Wallace-Gadsden F, Camilli A. Gene fitness landscapes of Vibrio cholerae at important stages of its life cycle. PLoS Pathog. 2013; 9(12):e1003800. doi: <u>10.</u> <u>1371/journal.ppat.1003800 PMID: 24385900</u>
- Matsunaga J, Lo M, Bulach DM, Zuerner RL, Adler B, Haake DA. Response of *Leptospira interrogans* to physiologic osmolarity: Relevance in signaling the environment-to-host transition. Infect Immun. 2007; 75(6):2864–74. doi: 10.1128/IAI.01619-06 PMID: 17371863
- Murray GL, Srikram A, Henry R, Hartskeerl RA, Sermswan RW, Adler B. Mutations affecting *Leptospira interrogans* lipopolysaccharide attenuate virulence. Mol Microbiol. 2010; 78(3):701–9. doi: <u>10.1111/j.1365-2958.2010.07360.x</u> PMID: 20807198
- Lin T, Gao L, Zhang C, Odeh E, Jacobs MB, Coutte L, et al. Analysis of an ordered, comprehensive STM mutant library in infectious *Borrelia burgdorferi*: insights into the genes required for mouse infectivity. PLoS One. 2012; 7(10):e47532. doi: 10.1371/journal.pone.0047532 PMID: 23133514
- Lehmann JS, Fouts DE, Haft DH, Cannella AP, Ricaldi JN, Brinkac L, et al. Pathogenomic inference of virulence-associated genes in *Leptospira interrogans*. PLoS Negl Trop Dis. 2013; 7(10):e2468. doi: 10.1371/journal.pntd.0002468 PMID: 24098822
- Koskiniemi S SS, Berg OG, Andersson DI. Selection-driven gene loss in bacteria. PLoS genetics. 2012; 8(6):e1002787. doi: 10.1371/journal.pgen.1002787 PMID: 22761588

- Morris JJ LR, Zinser ER. The Black Queen hypothesis: Evolution of dependencies through adaptive gene loss. mBio. 2012;2; 3(2). e00036–12. doi: 10.1128/mBio.00036-12 PMID: 22448042
- Sandoz KM, Mitzimberg SM, Schuster M. Social cheating in *Pseudomonas aeruginosa* quorum sensing. Proc Natl Acad Sci USA. 2007; 104(40):15876–81. doi: <u>10.1073/pnas.0705653104</u> PMID: 17898171
- 57. Caimano MJ, Sivasankaran SK, Allard A, Hurley D, Hokamp K, Grassmann AA, et al. A model system for studying the transcriptomic and physiological changes associated with mammalian host-adaptation by *Leptospira interrogans* serovar Copenhageni. PLoS Pathog. 2014; 10(3):e1004004. doi: 10.1371/ journal.ppat.1004004 PMID: 24626166
- Trzcinski K, Li Y, Weinberger DM, Thompson CM, Cordy D, Bessolo A, et al. Effect of serotype on pneumococcal competition in a mouse colonization model. mBio. 2015; 6(5):e00902–15. doi: 10.1128/ mBio.00902-15 PMID: 26374118
- Krumbeck JA, Marsteller NL, Frese SA, Peterson DA, Ramer-Tait AE, Hutkins RW, et al. Characterization of the ecological role of genes mediating acid resistance in *Lactobacillus reuteri* during colonization of the gastrointestinal tract. Environ Microbiol. 2015; 18(7):2172–84. doi: 10.1111/1462-2920.13108 PMID: 26530032
- **60.** Popat R, Crusz SA, Messina M, Williams P, West SA, Diggle SP. Quorum-sensing and cheating in bacterial biofilms. Proc Biol Sci / The Royal Society. 2012; 279(1748):4765–71.
- Wang M, Schaefer AL, Dandekar AA, Greenberg EP. Quorum sensing and policing of *Pseudomonas* aeruginosa social cheaters. Proc Natl Acad Sci USA. 2015; 112(7):2187–91. doi: 10.1073/pnas. 1500704112 PMID: 25646454
- Eshghi A, Pappalardo E, Hester S, Thomas B, Pretre G, Picardeau M. Pathogenic Leptospira interrogans exoproteins are primarily involved in heterotrophic processes. Infect Immun. 2015; 83(8):3061– 73. doi: 10.1128/IAI.00427-15 PMID: 25987703